生物学的製剤適正使用ガイド　病態理解に沿った治療選択

出版社： クリニコ出版
著者：
発行日： 2021-04-20
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784910396101
電子書籍版： 2021-04-20 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

6,160 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,160 円(税込)

購入する

商品紹介

本書では，免疫介在性疾患を俯瞰する意味を込めて，リウマチ・膠原病内科，消化器内科，呼吸器内科，整形外科，皮膚科など，生物学的製剤を活用している様々な分野のエキスパートに解説をお願いした。いずれの疾患も，概念，疫学，診断，診療ガイドラインが主要な生物学的製剤と関連づけられつつ，大変わかりやすく解説されている。

目次

  • I　総 論
    　関節リウマチ
    　全身性エリテマトーデス
    　脊椎関節炎
    　尋常性乾癬
    　クローン病および潰瘍性大腸炎
    　気管支喘息

    II　製剤別分類
    　1．TNF阻害薬
    　　関節リウマチ
    　　脊椎関節炎（強直性脊椎炎，乾癬性関節炎）
    　　尋常性乾癬
    　　ベーチェット病
    　　クローン病および潰瘍性大腸炎
    　　ぶどう膜炎
    　2．IL-6受容体阻害薬
    　　関節リウマチ
    　　全身型若年性特発性関節炎，成人スチル病
    　　キャッスルマン病
    　　高安動脈炎，巨細胞性動脈炎
    　3．IL-17阻害薬
    　　脊椎関節炎（強直性脊椎炎，乾癬性関節炎）
    　　尋常性乾癬
    　4．IL-12/IL-23阻害薬
    　　尋常性乾癬
    　　乾癬性関節炎
    　　クローン病
    　5．T細胞共刺激分子阻害薬
    　　関節リウマチ
    　6．B細胞阻害薬
    　　ANCA関連血管炎
    　　難治性ネフローゼ症候群
    　　特発性血小板減少性紫斑病
    　　全身性エリテマトーデス（べリムマブとリツキシマブ）
    　7．IL-1β阻害薬
    　　全身型若年性特発性関節炎
    　　周期性発熱症候群
    　8．IgE阻害薬
    　　気管支喘息
    　　アレルギー性鼻炎（スギ花粉症）
    　　慢性蕁麻疹
    　9．IL-5阻害薬
    　　気管支喘息
    　　好酸球性多発血管炎性肉芽腫症
    　10．IL-4/IL-13阻害薬
    　　アトピー性皮膚炎
    　　気管支喘息
    　11．生物学的製剤の安全性
    　　生物学的製剤投与前のスクリーニングと処置

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.14 掲載の参考文献
1) Yamanaka H, Sugiyama N, Inoue E, et al:Estimates of the Prevalence of and Current Treatment Practices for Rheumatoid Arthritis in Japan Using Reimbursement Data From Health Insurance Societies and the IORRA Cohort(I). Mod Rheum 24:33-40, 2014.
 
2) van de Stadt LA, de Koning MH, van de Stadt RJ, et al: Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 63:3226-3233, 2011.
 
3) du Montcel ST, Michou L, Petit-Teixeira E, et al:New Classification of HLA-DRB1 Alleles Supports the Shared Epitope Hypothesis of Rheumatoid Arthritis Susceptibility. Arthritis Rheum 52:1063-1068, 2005.
PubMed
4) Nishimura K, Sugiyama D, Kogata Y, et al:Meta-anal-ysis:Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheuma-toid Arthritis. Ann Intern Med 146:797-808, 2007.
 
5) van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al:Effects of Hydroxychloroquine and Sulphasalazine on Progression of Joint Damage in Rheumatoid Arthritis. Lancet 1:1036-1038, 1989.
PubMed
6) Arnett FC, Edworthy SM, Bloch DA, et al:The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum 31:315-324, 1988.
PubMed
7) Aletaha D, Neogi T, Silman AJ, et al:2010 Rheumatoid Arthritis Classification Criteria:An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis 69:1580-1588, 2010.
PubMed
8) Prevoo MA, van't Hof MA, Kuper HH, et al:Modified Disease Activity Scores That Include Twenty-Eight-Joint Counts. Development and Validation in a Prospective Longitudinal Study of Patients With Rheumatoid Arthritis. Arthritis Rheum 38:44-48, 1995.
 
9) Deighton C Hyrich K, Ding T, et al:BSR and BHPR Rheumatoid Arthritis Guidelines on Eligibility Criteria for the First Biological Therapy. Rheumatology(Oxford) 49:1197-1199, 2010.
PubMed
10) Pincus T, Brooks RH, Callahan LF:Prediction of Long-Term Mortality in Patients With Rheumatoid Arthritis According to Simple Questionnaire and Joint Count Measures. Ann Intern Med 120:26-34, 1994.
PubMed
11) Smolen JS, Landewe RBM, Bijlsma JWJ, et al:EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs:2019 Update. Ann Rheum Dis 2020 Jan 22:annrheumdis-2019-216655. doi:10.1136/annrheumdis-2019-216655(Online ahead of print).
 
P.20 掲載の参考文献
1) Tsokos GC:Systemic lupus erythematosus. N Engl J Med 365:2110-2121, 2011.
PubMed
2) Liu Z, Davidson A:Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med 18:871-882, 2012.
PubMed
3) Hochberg MC:Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725, 1997.
PubMed
4) Petri M, Orbai A, Icenberg D, et al:Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677-2686, 2012.
 
5) Aringer M, Costenbader K, Daikh D, et al:2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71:1400-1412, 2019.
PubMed
6) Bombardier C, Gladman DD, Urowitz, et al:Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630-640, 1992.
 
7) Symmons DP, Coppock JS, Bacon PA, et al:Develop-ment and assessment of a computerized index of clini-cal disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 69:927-937, 1988.
 
8) Petri M, Kim MY, Kalunianet KC, et al:Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550-2558, 2005.
 
9) 厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究(自己免疫班), 日本リウマチ学会編:全身性エリテマトーデス診療ガイドライン 2019. 南山堂, 東京. 2019.
 
10) Fanouriakis A, Kostopoulon M, Cheema K, et al:2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association(EULAR/ERA-EDTA)recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713-723, 2020.
 
11) Hahn BH, McMahon MA, Wilkinson A, et al:American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res(Hoboken)64:797-808, 2012.
PubMed
12) van Vollenhoven RF, Mosca M, Bertias G, et al: Treat-to-target in systemic lupus erythematosus:recommendations from an international task force. Ann Rheum Dis 73:958-967, 2014.
 
13) Zhang F, Bae SC, Bass D, et al:A pivotal phase III randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77:355-363, 2018.
 
P.36 掲載の参考文献
1) Han C, Robinson DW Jr, Hackett MV, et al:Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167-2172, 2006.
PubMed
2) Erbil J, Espinoza LR:Nonradiographic axial spondy-loarthritis background and confounding factors of this new terminology:an appraisal. Clin Rheumatol 34: 407-411, 2015.
 
3) Zeidler H, Amor B:The Assessment in Spondyloarthri-tis International Society(ASAS)classifi cation criteria for peripheral spondyloarthritis and for spondyloarthri-tis in general:the spondyloarthritis concept in prog-ress. Ann Rheum 70:1-3, 2011.
 
4) 脊椎関節炎診療の手引き 2020.日本脊椎関節炎学会 厚生労働科学研究費補助金(難治性疾患政策研究事業)「強直性脊椎炎に代表される脊椎関節炎の疫学調査・診断基準作成と診療ガイドライン策定を目指した大規模多施設研究」班編. 診断と治療社, 東京. 2020.
 
5) McGonagle DG, Mclnnes IB, Kirkham BW, et al:The role of IL-17A in axial spondyloarthritis and psoriatic arthritis:recent advances and controversies. Ann Rheum Dis 78(9):1167-1178, 2019.
 
6) Brembilla NC, , Senra L, Boehncke WH, et al:The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol 9:1-13, 2018.
 
7) Marinori B, Ceribelli A, Massarotti MS, et al:The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights 5(1):9-19, 2014.
 
8) Calin A, Porta J, Fries JF, et al:Clinical history as a screening test for ankylosing spondylitis. JAMA 237:2613-2614, 1977.
PubMed
9) Rudwaleit M, Metter A, Listing J, et al:Inflammatory back pain in ankylosing spondylitis:a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54:569-578, 2006.
PubMed
10) Sieper J, Rudwaleit M, Baraliakos X, et al:The Assessment of SpondyloArthritis international Society (ASAS)handbook:a guide to assess spondyloarthritis. Ann Rheum Dis 68(Suppl 2):ii1-44, 2020.
 
11) Van der Linden S, Valkenburg HA, Cats A:Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368, 1984.
PubMed
12) Garrett S, Jenkinson T, Kennedy LG, et al:A new approach to defining disease status in ankylosing spondylitis:the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286-2291, 1994.
PubMed
13) Lukas C, Landewe R, Sieper J, et al:Development of an ASAS-endorsed disease activity score(ASDAS)in patients with ankylosing spondylitis. Ann Rheum Dis 68:18-24, 2009.
PubMed
14) van der Heijde D, Lie E, Kvien TK, et al:ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811-1818, 2009.
PubMed
15) Maohado P, Navarro-Compan V, Landewe R, et al:Brief Report:Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional C-Reactive Protein Level Is Below the Limit of Detection or If High-Sensitivity C-Reactive Protein Is Used:An Analysis in the DESIR Cohort. Arthritis Rheumatol 67:408-413, 2015.
PubMed
16) van der Heijde D, Ramiro S, Landewe R, et al:2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978-991, 2020.
 
17) Ward MM, Deodhar A, Gensler LS, et al:2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 71:1599-1613, 2019.
PubMed
18) Taylor W , Gladman D, Helliwell P, et al:Classification criteria for psoriatic arthritis:development of new criteria from a large international study. Arthritis Rheum 54(8):2665-2673, 2006.
 
19) Coates LC, Fransen J, Helliwell PS:Defining minimal disease activity in psoriatic arthritis:a proposed objective target for treatment. Ann Rheum Dis 69:48-53, 2010.
PubMed
20) Coates LC, Kavanaugh A, Mease P, et al:Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 68:1060-1071, 2016.
 
21) Gossec L, Baraliakos X, Kerschbaumer A, et al:EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies:2019 update. Ann Rheum Dis 79:700-712, 2020.
PubMed
P.41 掲載の参考文献
1) Ito H, Takahashi H, Kawada A, et al:Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol 45:293-301, 2018.
 
2) 佐野栄紀:乾癬の免疫学的病態. 日本臨床 76:22-27, 2018.
Medical*Online
3) Boehncke WH, Schon MP:Psoriasis. Lancet 386:983-94, 2015.
PubMed
4) 藤本学:乾癬. 免疫・炎症病態×治療 Update. 熊ノ郷淳編. 南山堂, 東京. p150-156, 2019.
 
5) Fredriksson T, Pettersson U:Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157(4):238-244, 1978.
PubMed
6) Finlay AY:Current severe psoriasis and the rule of tens. Br J Dermatol 152:861-867, 2005.
PubMed
7) 飯塚一:乾癬治療のピラミッド計画. 日皮会誌 116:1285-93, 2006.
 
8) Armstrong AW, Puig L, Joshi A, et al:Comparison of biologics and oral treatments for plaque psoriasis:A meta-analysis. JAMA Dermatol 156:258-269, 2020.
PubMed
P.51 掲載の参考文献
1) 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」(鈴木班). 令和元年度分担研究報告書 潰瘍性大腸炎・クローン病 診断基準・治療指針(令和元年度 改訂版)(http://www.ibdjapan.org/)
 
2) Murakami Y, Nishiwaki Y, Oba MS, et al:Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014:an analysis of a nationwide survey. J Gastroenterol 54(12):1070-1077, 2019.
PubMed
3) D'Haens G, Ferrante M, Vermeire S, et al:Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18(12):2218-2224, 2012.
PubMed
4) Shinzaki S, Matsuoka K, Iijima H, et al:Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis 11(1):84-91, 2017.
PubMed
5) Satsangi J, Silverberg MS, Vermeire S, et al:The Montreal classification of inflammatory bowel disease:controversies, consensus, and implications. Gut 55:749-753, 2006.
PubMed
6) Best WR, Becktel JM, Singleton JW, et al:Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70:439-444, 1976.
PubMed
7) Harvey RF, Bradshaw JM:A simple index of Crohn's-disease activity. Lancet 1(8167):514, 1980.
 
8) Mary JY, Modigliani R:Development and validation of an endoscopic index of the severity for Crohn's disease:a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections. Inflammatoires du Tube Digestif(GETAID). Gut 30:983-989, 1989.
 
9) Daperno M, D'Haens G, Van Assche G, et al: Development and validation of a new, simplified endoscopic activity score for Crohn's disease:the SES-CD. Gastrointest Endosc 60:505-512, 2004.
PubMed
10) Schroeder KW, Tremaine WJ, Ilstrup DM:Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625-1629, 1987.
PubMed
11) Lichtiger S, Present DH:Preliminary report:cyclosporin in treatment of severe active colitis. Lancet 336:16-19, 1990.
PubMed
12) Travis SP, Schnell D, Krzeski P, et al:Developing an instrument to assess the endoscopic severity of ulcerative colitis:the Ulcerative Colitis Endoscopic Index of Severity(UCEIS). Gut 61:535-542, 2012.
PubMed
13) 難病情報センター・ホームページ(https://www.nanbyou.or.jp/entry/219)
 
P.57 掲載の参考文献
1) Nakamura Y, Tamaoki J, Yamaguchi M, et al:Japanese guidelines for adult asthma 2020. Allergol Int 69:519-548, 2020.
PubMed
2) 2020 GINA Report, Global Strategy for Asthma Management and Prevention.
 
3) 日本呼吸器学会・日本アレルギー学会:成人気管支喘息における生物学的製剤の適正使用ステートメント. 2020年5月.
 
4) 日本アレルギー学会:ダニアレルギーにおけるアレルゲン免疫療法の手引き(改訂版). 日本アレルギー学会「ダニアレルギーにおけるアレルゲン免疫療法の手引き」作成委員会編.メディカルレビュー社, 東京. 2018.
 

II 製剤別分類

P.65 掲載の参考文献
1) Aletaha D, Smollen JS:Diagnosis and Management of Rheumatoid Arthritis:A Review. JAMA 320:1360-1372, 2018.
 
2) McInnes IB, Schett G:Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389:2328-2337, 2017.
PubMed
3) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al:Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis(the BeSt study):a randomized, controlled trial. Arthritis Rhuem 52:3381-3390, 2005.
 
4) Moots RJ, Xavier RM, Mok CC, et al:The impact of anti-drug antibodies on drug concentrations and clinicaloutcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One 12:e0175207, 2017.
PubMed
5) Tanaka Y, Takeuchi T, Mimori T, et al:Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA)study. Ann Rheum Dis 69:1286-1291, 2010.
PubMed
6) Emery P, Hammoudeh M, FitzGerald O, et al: Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 371:1781-1792, 2014.
PubMed
7) Kavanaugh A, Fleischmann RM, Emery P, et al: Clinical, Functional and Radiographic Consequences of Achieving Stable Low Disease Activity and Remission With Adalimumab Plus Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis:26-week Results from the Randomised, Controlled OPTIMA Study. Ann Rheum Dis 72:64-71, 2013.
PubMed
8) Sammaritano LR, Bermas BL, Chakravarty EE, et al:2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheum 2020 (Online ahead).
 
9) Atsumi T, Tanaka Y, Yamamoto K, et al:Clinical Benefit of 1-year Certolizumab Pegol(CZP)Add-On Therapy to Methotrexate Treatment in Patients With Early Rheumatoid Arthritis Was Observed Following CZP Discontinuation: 2-year Results of the C-OPERA Study, a Phase III Randomised Trial. Ann Rheum Dis 76:1348-1356, 2017.
 
10) Kerschbaumer A, Sepriano A, Smolen JS, et al:Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Research Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis. Ann Rheum Dis annrheumdis-2019-216656. doi:10.1136/annrheumdis-2019-216656, 2020(Online ahead of print).
 
11) Smolen JS, Landewe RBM, Bijlsma JWJ, et al:EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs:2019 Update. Ann Rheum Dis annrheumdis-2019-216655. doi:10.1136/annrheumdis-2019-216655, 2020(Online ahead of print).
 
12) Smolen JS, Aletaha D:Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges. Nat Rev Rheumato 11:276-289, 2015.
 
13) Gottenberg JE, Brocq O, Perdriger A, et al:Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug:A Randomized Clinical Trial. JAMA 316:1172-1180, 2016.
 
14) Smolen JS, Burmester GR, Combe B, et al:Head-to-Head Comparison of Certolizumab Pegol Versus Adalimumab in Rheumatoid Arthritis:2-year Efficacy and Safety Results From the Randomised EXXELERATE Study. Lancet 388:2763-2774, 2016.
PubMed
15) Hashimoto M, Furu M, Yamamoto W, et al:Factors Associated With the Achievement of Biological Disease-Modifying Antirheumatic Drug-Free Remission in Rheumatoid Arthritis:The ANSWER Cohort Study. Arthritis Res Ther 20:165, 2018.
PubMed
16) Fautrel B, Pham T, Alfaiate T, et al:Step-down Strategy of Spacing TNF-blocker Injections for Established Rheumatoid Arthritis in Remission:Results of the Multicentre Non-Inferiority Randomised Open-Label Controlled Trial(STRASS:Spacing of TNF-blocker Injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 75:59-67, 2016.
PubMed
17) Harrold LR, Litman HJ, Connolly SE, et al:Compara-tive Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthri-tis Who Are Anti-CCP Positive in the United States Corrona Registry. Rheumatol Ther 6:217-230, 2019.
 
18) Greenberg JD, Kremer JM, Curtis JR, et al:Tumour Necrosis Factor Antagonist Use and Associated Risk Reduction of Cardiovascular Events Among Patients With Rheumatoid Arthritis. Ann Rheum Dis 70:576-582, 2011.
PubMed
19) Sutcliffe M, Radley G, Barton A:Personalized Medicine in Rheumatic Diseases: How Close Are We to Being Able to Use Genetic Biomarkers to Predict Response to TNF Inhibitors? Expert Rev Clin Immunol 16:389-396, 2020.
 
20) Guan Y, Zhang H, Quang D, et al:Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers. Arthritis Rheum 71:1987-1996, 2019.
 
21) 日本リウマチ学会:関節リウマチ(RA)に対するTNF阻害薬使用の手引き(2020年2月1日改訂版). 2020.
 
22) Singh JA, Saag KG, Bridges SL Jr, et al:2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 68:1-25, 2016.
PubMed
P.72 掲載の参考文献
1) 日本リウマチ学会 調査研究委員会 生物学的製剤使用ガイドライン策定小委員会:強直性脊椎炎(AS)に対するTNF阻害療法施行ガイドライン(2010年10月改訂版).
 
2) 脊椎関節炎診療の手引き2020. 日本脊椎関節炎学会・厚生労働科学研究費補助金(難治性疾患政策研究事業)「強直性脊椎炎に代表される脊椎関節炎の疫学調査・診断基準作成と診療ガイドライン策定を目指した大規模多施設研究」班編. 診断と治療社, 東京. 2020.
 
3) Garrett S, Jenkinson T, Kennedy LG, et al:A new approach to defining disease status in ankylosing spondylitis:the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286-2291, 1994.
PubMed
4) Machado PM, Landewe R, van der Heijde D;Assessment of SpondyloArthritis international Society (ASAS):Ankylosing Spondylitis Disease Activity Score(ASDAS):2018 update of the nomenclature for disease activity states. Ann Rheum Dis 77(10):1539-1540, 2018.
 
5) Brandt J1, Listing J, Sieper J, et al:Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 63:1438-1444, 2004.
 
6) van der Heijde D, Dijkmans B, Geusens P, et al:Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial(ASSERT). Arthritis Rheum 52:582-591, 2005.
 
7) van der Heijde D, Kivitz A, Schiff MH, et al:ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis:results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136-2146, 2006.
 
8) Sieper J, van der Heijde D, Dougados M, et al:Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71:700-706, 2012.
PubMed
9) Coates LC, Kavanaugh A, Mease PJ, et al:Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 68:1060-1071, 2016.
 
10) Gossec L, Baraliakos X, Kerschbaumer A, et al:EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies:2019 update. Ann Rheum Dis 79:700-712, 2020.
PubMed
11) 乾癬性関節炎診療ガイドライン2019. 日本皮膚科学会乾癬性関節炎診療ガイドライン作成委員会・厚生労働科学研究費補助金 難治性疾患等政策研究事業 乾癬性関節炎研究班調査研究委員会編. 2019.
 
12) Felson DT, Anderson JJ, Boers M, et al:American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727-735, 1995.
PubMed
13) Antoni CE, Kavanaugh A, Kirkham B, et al:Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis:results from the infliximab multinational psoriatic arthritis controlled trial(IMPACT). Arthritis Rheum 52:1227-1236, 2005.
PubMed
14) Mease PJ, Gladman DD, Ritchlin CT, et al:Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279-3289, 2005.
 
15) Mease PJ, Ory P, Sharp JT, et al:Adalimumab for long-term treatment of psoriatic arthritis:2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial(ADEPT). Ann Rheum Dis 68:702-709, 2009.
PubMed
16) Coates LC, Moverley AR, McParland L, et al:Effect of tight control of inflammation in early psoriatic arthritis (TICOPA):a UK multicentre, open-label, randomised controlled trial. Lancet 386:2489-2498, 2015.
 
17) Mease PJ, Fleischmann R, Deodhar AA, et al:Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis:24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48-55, 2014.
PubMed
18) van der Heijde D, Fleischmann R, Wollenhaupt J, et al:Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis:results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 73:233-237, 2014.
PubMed
19) van der Heijde D, Deodhar A, FitzGerald O, et al:4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 4:e000582, 2018.
PubMed
P.81 掲載の参考文献
1) 大槻マミ太郎, 佐伯秀久, 照井正ほか:乾癬における生物学的製剤の使用ガイダンス(2019年版). 日皮会誌 129:1845-1864, 2019.
 
2) Papp K, Menter A, Poulin Y, et al:J Long-term out-comes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis:subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol 27:634-642, 2013.
 
3) Reich K, Ortonne J-P, Gottlieb AB, et al:Successful treatment of moderate to severe plague psoriasis with the PEGylated Fab' certolizumab pegol:results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 167:180-190, 2012.
 
4) 渡辺彰:結核, 非結核性(非定型)抗酸菌症の予防と治療の実際. リウマチ科 37:356-364, 2007.
 
5) 日本リウマチ学会・リウマチ性疾患治療薬検討委員会:関節リウマチ(RA)に対するTNF阻害療法施行ガイドライン(2018年改訂版). 日本リウマチ学会ホームページ 2018.
 
6) 日本肝臓学会 肝炎診療ガイドライン作成委員会:B型肝炎治療ガイドライン(第3版):資料3 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン. 日本肝臓学会ホームページ 2017.
 
7) Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al:The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795-810, 2016.
PubMed
P.89 掲載の参考文献
1) 岳野光洋:ベーチェット病. 山本一彦, 田中栄;日本リウマチ財団教育研修委員会・リウマチ学生涯教育委員会編. リウマチ病学テキスト第2版. 診断と治療社, 東京. p400-408, 2016.
 
2) Yazici H, Seyahi E, Hatemi G, et al:Behcet syndrome:a contemporary view. Nat Rev Rheumatol 14:119, 2018.
PubMed
3) 厚生労働科学研究費補助金(難治性疾患政策研究事業)ベーチェット病に関する調査研究班, 厚生労働科学研究費補助金(難治性疾患政策研究事業)難治性炎症性両障害に関する調査研究班:ベーチェット病診療ガイドライン2020. 日本ベーチェット病学会監修. 水木信久, 竹内正樹責任編集. 診断と治療社, 東京.2020.
 
4) Hatemi G, Christensen R, Bang D, et al:2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 77:808-818, 2018.
PubMed
5) Ohno S, Nakamura S, Hori S, et al:Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31:1362-1368, 2004.
PubMed
6) Sfikakis PP, Elezoglou A, Katsilambros N, et al:Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 140:404-406, 2004.
PubMed
7) Tugal-Tutkun I, Mudun A, Urgancioglu M, et al:Ef-ficacy of infliximab in the treatment of uveitis that is refractory to treatment with the combination of aza-thioprine, cyclosporine, and corticosteroids in Behcet's disease. An open-label trial. Arthritis Rheum 52:2478-2484, 2005.
 
8) Okada AA, Goto H, Ohno S, et al:Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 130:592-598, 2012.
PubMed
9) Takeuchi M, Kezuka T, Sugita S, et al:Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet's disease:a multicenter study. Ophthalmology 121:1877-1884, 2014.
 
10) Levy-Clarke G, Jabs DA, Read RW, et al:Expert panel recommendations for the use of anti-tumor necrosis fac-tor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785-796, 2014.
 
11) Markomichelakis N, Delica E, Masselos S, et al:A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative 4-week study. Rheumatology 50:593-597, 2011.
 
12) Calvo-Rio V, Balnco R, Beltran E, et al:Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease:a 1-year follow-up study of 124 patients. Rheumatology 53:2223-2231, 2014.
 
13) Magro-Checa C, Salvatierra J, Rosales-Alexander JL, et al:Life-threatening vasculo-Behcet following discontinuation of infliximab after three years of complete remission. Clin Exp Rheumatol 31(3 Suppl 77):96-98, 2013.
 
14) Kirino Y, Ideguchi H, Takeno M, et al:Continuous evolution of clinical phenotype in 578 Japanese patients with Behcet's disease:a retrospective observational study. Arthritis Res Ther 18:21, 2016.
 
15) Naganuma M, Sakuraba A, Hisamatsu T, et al:Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 14:1259-1264, 2008.
PubMed
16) Hibi T, Hirohata S, Kikuchi T, et al:Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter prospective, open-label, single-arm phase 3 study. Medicine 95:e3863, 2016.
 
17) Lee JH, Choe JH, Jeon SW et al:Efficacy of infliximab in intestinal Behcet's disease:a Korean multicenter retrospective study. Inflamm Bowel Dis 19:1833-1838, 2013.
 
18) Tanida S, Inoue N, Kobayashi K, et al:Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clinical gastroenterology and hepatology 13:940-948, 2015.
PubMed
19) Miyagawa I, Nakano K, Iwata S, et al:Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease. Arthritis Res Ther 21:151, 2019.
PubMed
20) Lee HW, Choe JH, Lee HJ, et al:Postoperative Effects of Thiopurines in Patients with Intestinal Behcet's Disease. Dig Dis Sci 60:3721-3727, 2015.
 
21) Saadoun D, Wechsler B, Desseaux K, et al:Mortality in Behcet's disease. Arthritis Rheum 62:2806-2812, 2010.
PubMed
22) Adler S, Baumgartner I, Villiger PM:Behcet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res(Hoboken)64:607, 2012.
PubMed
23) Hamuryudan V, Seyahi E, Ugurlu S, et al:Pulmonary artery involvement in Behcet's syndrome:Effects of anti-Tnf treatment. Semin Arthritis Rheum 45(3):369-373, 2015.
PubMed
24) Emmi G, Vital A, Silvestri E, et al:Adalimumab-based treatment versus DMARDs for venous thrombosis in Behcet syndrome:A retrospective study of 70 patients with vascular involvement. Arthritis Rheumatol 70(9):1500-1507, 2018.
 
25) Seyahi E, Hamuryudan V, Hatemi G, et al:Infliximab in the treatment of hepatic vein thrombosis(Budd-Chiari syndrome)in three patients with Behcet's syndrome. Rheumatology(Oxford)46:1213-1214, 2007.
PubMed
26) Hirohata S, Kikuchi H, Sawada T, et al:Clinical characteristics of neuro-Behcet's disease in Japan:a multicenter retrospective analysis. Mod Rheumatol 22:405-413, 2012.
PubMed
27) Hirohata S, Kikuchi H, Sawada T, et al:Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 24:961-965, 2014.
PubMed
28) Hirohata S, Kikuchi H, Sawada T, et al:Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. J Neurol Sci 349:143-148, 2015.
PubMed
29) Fujikawa K, Arataka K, Kawakami A, et al:Successful treatment of refractory neuro-Behcet's disease with infliximab:a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 66:136-137, 2007.
 
30) Di Filippo M, Gregorio M, Nannini C, et al:Infliximab monotherapy for neuro-Behcet's disease:a case report. J Neurol Sci 347:389-390, 2014.
 
31) Desbois AC, Addimanda O, Bertand A, et al:Efficacy of Anti-TNFα in Severe and Refractory Neuro-Behcet Disease:An Observational Study. Medicine(Baltimore) 95(23):e3550, 2016.
 
32) Zeydan B, Urygunoglu U, Saip S, et al:Infliximab is a plausible alternative for neurologic complications of Behcet disease. Neurol Neuroimmunol Neuroinflamm 3(5):e258, 2016.
PubMed
33) Kikuchi H, Aramaki K, Hirohata S, et al:Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 272:99-105, 2008.
PubMed
34) Melikoglu M, Fresko I, Mat C, et al:Short-term trial of etanercept in Behcet's disease:a double blind, placebo controlled study. J Rheumatol 32:98-105, 2005.
PubMed
35) Connolly M, Armstrong JS, Buckley DA, et al: Infliximab treatment for severe orogenital ulceration in Behcet's disease. Br J Dermatol 153:1073-1075, 2005.
 
36) Sfikakis PP, Markomichelakis N, Alpsoy E, et al:Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford)46:736-741, 2007.
 
37) Arida A, Fragiadaki K, Giavri E, et al:Anti-TNF agents for Behcet's disease:analysis of published data on 369 patients. Semin Arthritis Rheum 41:61-70, 2011.
PubMed
38) Ozugler Y, Leccese P, Christensen R, et al:Management of major organ involvement of Behcet's syndrome:a systematic review for update of the EULAR recommendations. Rheumatology(Oxford)57(12):2200-2212, 2018.
 
39) Caso F, Costa L, Rigante D, et al:Biological treatments in Behcet's disease: beyond anti-TNF therapy. Mediators Inflamm 2014:107421, 2014.
PubMed
40) Sota J, Rigante D, Lopalco G, et al:Biological therapies for the treatment of Behcet's disease related uveitis beyond TNF alpha blockade:a narrative review Rheumatol Int 38:25-35, 2018.
PubMed
P.100 掲載の参考文献
1) Ni J, Wu GD, Albenberg L, et al:Gut microbiota and IBD:causation or correlation? Nat Rev Gastroenterol Hepatol 14:573-584, 2017.
PubMed
2) Palladiano M, Bahjat F, Theodorakis E, et al:Anti-TNF-alpha therapies:the generation. Nat Rev Drug Discov 2:736-746, 2003.
 
3) Renna S, Cottone M, OrlandoA:Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 20:9675-9690, 2014.
PubMed
4) Hanauer SB, Feagan BG, Lichtenstein GR, et al: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541-1549, 2002.
PubMed
5) Sands BE, Anderson FH, Bernstein CN, et al: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350:876-885, 2004.
PubMed
6) Rutgeerts P, Sandborn WJ, Feagan BG, et al:Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462-2476, 2005.
PubMed
7) Colombel JF, Sandborn WJ, Reinisch W, et al:Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362:1383-1395, 2010.
 
8) Panaccione R, Ghosh S, Middleton S, et al:Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146:392-400. e3, 2014.
 
9) Hanauer SB, Sandborn WJ, Rutgeerts P, et al:Human anti-tumor necrosis factor monoclonal antibody (adalimumab)in Crohn's disease:the CLASSIC-I trial. Gastroenterology 130:323-333, 2006.
PubMed
10) Sandborn WJ, Rutgeerts P, Enns R, et al:Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829-838, 2007.
PubMed
11) Colombel JF, Sandborn WJ, Rutgeerts P, et al:Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132:52-65, 2007.
PubMed
12) Watanabe M, Hibi T, Lomax KG, et al:Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis 6:160-173, 2012.
PubMed
13) Reinisch W, Sandborn WJ, Hommes DW, et al:Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis:results of a randomised controlled trial. Gut 60:780-787, 2011.
PubMed
14) Sandborn WJ, van Assche G, Reinisch W, et al: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142:257-265, 2012.
PubMed
15) Suzuki Y, Motoya S, Hanai H, et al:Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 49:283-294, 2014.
PubMed
16) Matsumoto T, Motoya S, Watanabe K, et al:Adalimumab monotherapy and a combination with azathioprine for Crohn's disease:a prospective, randomized trial. J Crohns Colitis 10:1259-1266, 2016.
 
17) Watanabe K, Matsumoto T, Hisamatsu T, et al:Clinical and pharmacokinetic factors associated with Adalimumab-induced mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol 16:542-549, 2018.
PubMed
18) Sandborn WJ, Feagan BG, Marano C, et al:Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85-95, 2014.
PubMed
19) Sandborn WJ, Feagan BG, Marano C, et al:Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:96-109, 2014.
PubMed
20) Hibi T, Imai Y, Senoo A, et al:Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis:a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). J Gastroenterol 52:1101-1111, 2017.
PubMed
21) Taxonera C, Rodriguez C, Bertoletti F, et al:Clinical outcomes of Golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis. Inflamm Bowel Dis 23:1394-1402, 2017.
 
22) Papamichael K, Gils A, Rutgeerts P, et al:Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD:evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 21:182-197, 2015.
PubMed
23) Parakkal D, Sifuentes H, Semer R, et al:Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy:expanding the groups at risk. Eur J Gastroenterol Hepatol 23:1150-1156, 2011.
 
24) Singh JA, Saag KG, Bridges SL Jr, et al:2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 68:1-25, 2016.
PubMed
25) Cheifetz A, Mayer L:Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 72:250-256, 2005.
PubMed
26) Steenholdt C, Molazahi A, Ainsworth MA, et al:Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinic remission: an observational Danish sigle center study. Scand J Gastroenterol 47:518-527, 2012.
 
P.108 掲載の参考文献
1) 日本眼炎症学会ぶどう膜炎診療ガイドライン作成委員会:ぶどう膜炎診療ガイドライン. 日眼会誌 123:635-696, 2019.
 
2) Rosenbaum JT, Duck AD:The Eyes Have It:A Rheumatologist's View of Uveitis. Arthritis Rheumatol 70(10):1533-1543, 2017.
 
3) 日本眼炎症学会 TNF阻害薬使用検討委員会:非感染性ぶどう膜炎に対するTNF阻害薬使用指針および安全対策マニュアル(改訂第2版, 2019年版). 日眼会誌 123:697-705, 2019.
 
4) Merida S, Palacios E, Navea A, et al:New Immunosup-pressive Therapies in Uveitis Treatment Int J Mol Sci 16:18778-18795, 2015.
 
5) Cordero-Coma M, Sobrin L:Anti-tumor necrosis factor-a therapy in uveitis. Surv Ophthalmol 60:575-589, 2015.
 
6) Ohno S, Nakamura S, Hori S, et al:Efficacy, safety, and pharmacokinetics of multiple administration of inflix-imab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31:1362-1368, 2004
 
7) Okada AA, Goto H, Ohno S, et al:Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 130:592-598, 2012.
PubMed
8) Jaffe GJ, Dick AD, Brezin AP, et al:Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 375:932-943, 2016.
PubMed
9) Nguyen QD, Merrill PT, Jaffe GJ, et al:Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids(VISUAL II):a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388:1183-1192, 2016.
 
10) 日本ベーチェット病学会:ベーチェット病診療ガイドライン2020. 水木信久, 竹内正樹編. 診断と治療社. 東京. p1-183, 2020.
 
11) Vitale A, Emmi G, Lopalco G, et al:Adalimumab effectiveness in Behcet's disease:short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36:451-455, 2017.
 
12) Couto C, Schlaen A, Frick M, et al:Adalimumab Treat-ment in Patients with Vogt-Koyanagi-Harada Disease. Ocul Immunol Inflamm 26:485-489, 2018.
 
13) Erckens RJ, Mostard RLM, Wijnen PAHM, et al: Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis Arch Clin Exp Ophthalmol 250:713-720, 2012.
PubMed
14) Takeuchi T, Tatsuki Y, Nogami Y, et al:Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67:189-194, 2008.
PubMed
15) Koike T, Harigai M, Ishiguro N, et al:Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol 24:390-398, 2014.
PubMed
16) 日本肝臓学会肝炎診療ガイドライン作成委員会:B型肝炎治療ガイドライン(第3.3版:2021年1月改訂)(http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b).
 
P.112 掲載の参考文献
1) Nishina N, Kaneko Y, Kameda H, et al:Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin Rheumatol 32:1661-1661, 2013.
 
2) Robak T, Gladalska A, Stepien H, et al:Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Media-tors Inflamm 7:347-353, 1998.
 
3) Nishina N, Kikuchi J, Hashizume M, et al:Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implication for molecular targeted therapy. Ann Rheum Dis 73:945-947, 2014.
PubMed
4) Jones G, Sebba A, Gu J, et al:Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88-96, 2010.
PubMed
5) Tanaka Y, Wada K, Takahashi Y, et al:Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther 21:79, 2019.
PubMed
6) Kameda H, Wada K, Takahashi Y, et al:Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: a Japan phase 3 trial(HARUKA). Mod Rheumatol 30(2):239-248, 2020.
PubMed
7) 一般社団法人日本リウマチ学会ガイドライン委員会. RA治療薬ガイドライン小委員会(委員長川人豊):関節リウマチ(RA)に対するIL-6阻害薬使用の手引き 2020年2月改訂 第10版(https://www.ryumachi-jp.com/info/guideline_IL-6.pdf).
 
8) Dougados M, Kissel K, Conaghan PG, et al:Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis:the ACT-RAY study. Ann Rheum Dis 73:803-809, 2014.
PubMed
9) Kaneko Y, Atsumi T, Tanaka Y, et al:Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate:52-week results from a prospective, randomized, controlled study (SURPRISE study). Ann Rheum Dis 75:1917-1923, 2016.
PubMed
10) Bijlsma JWJ, Welsing PMJ, Woodworth TG, et al: Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination(U-Act-Early):a multicentre, randomized, double-blind, double-dummy, strategy trial. Lancet 388:343-355, 2016.
PubMed
11) Gabay C, Emery P, van Vollenhoven R, et al:Tocili-zumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis(ADACTA):a randimised, double-blind, controlled phase 4 trial. Lancet 381:1541-1550, 2013.
 
12) Burmester GR, Lin Y, Patel R, et al:Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis(MONARCH):a randomized, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:840-847, 2017.
 
13) Smolen JS, Landewe RBM, Bijlsma JWJ, et al:EULAR recommendations for the management of rheumatoid arthritis with systemic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685-699, 2020.
 
14) Emery P, Keystone E, Tony HP, et al:IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis 67:1516-1523, 2008.
PubMed
15) Fleischmann R, van Adelsberg J, Lin Y, et al:Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol 69:277-290, 2017.
 
16) Ogata A, Tanaka Y, Ishii T, et al:A randomized, double-blind, parallel-group, phase III stidy of shortenin the dose interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. Mod Rheumatol 28:76-84, 2018.
 
17) Finzel S, Kraus S, Figueiredo CP, et al:Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis 78:1186-1191, 2019.
 
18) Koike T, Harigai M, Inokuma S, et al:Effectiveness and safety of tocilizumab:postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41:15-23, 2014.
PubMed
19) Emery P, Rondon J, Parrino J, et al:Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology 58:849-858, 2019.
PubMed
P.118 掲載の参考文献
1) Still GF:On a Form of chronic Joint Disease in Children. Med Chir Trans 80:47-69, 1897.
PubMed
2) Bywaters EG:Still disease in adult. Ann Rheum Dis 30(2):121-133, 1971.
PubMed
3) Petty RE, Southwood TR, Manners P, et al:Interna-tional League of Associations for Rheumatology Classi-fication of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumtol 31:390-392, 2004.
 
4) Yamaguchi M, Ohta A, Tsunematsu T, et al:Preliminary criteria for classification of adult Still's disease. J Rheumatol 19(3):424-430, 1992.
 
5) Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al:Adult-onset Still's disease. Autoimmun Rev 13:708-722, 2014.
PubMed
6) Mangge H, Schauenstein K: Cytokines in juvenile rheumatoid arthritis(JRA). Cytokine 10(6):471-480, 1998.
PubMed
7) Fujii T, Nojima T, Yasuoka H, et al:Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology(Oxford)40(12):1398-1404, 2001.
PubMed
8) Chen DY, Lan JL, Lin FL, et al:Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 63(10):1300-1306, 2004.
 
9) Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al: Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Immunol Res 61:53-62, 2015.
PubMed
10) Yokota S, Imagawa T, Mori M, et al:Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998-1006, 2008.
PubMed
11) Kaneko Y, Kameda H, Ikeda K, et al:Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77:1720-1729, 2018.
PubMed
12) Ravelli A, Minoia F, Davi S, et al:2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 68(3):566-576, 2016.
PubMed
P.123 掲載の参考文献
1) Castleman B, Iverson L, Menendez VP:Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9:822-830, 1956.
PubMed
2) Bartoli E, Massarelli G, Soggia G, et al:Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 73:423-426, 1980.
PubMed
3) Dispenzieri A, Fajgenbaum DC:Overview of Castleman Disease. Blood 135:1353-1364, 2020.
PubMed
4) Ulbright TM, Santa Cruz DJ:Kaposi's sarcoma: relationship with hematologic, lymphoid, and thymic neoplasia. Cancer 47:963-973, 1981.
PubMed
5) Lachant NA, Sun NC, Leong LA, et al:Multicentric an-giofollicular lymph node hyperplasia(Castleman's dis-ease)followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol 83:27-33, 1985.
 
6) Soulier J, Grollet L, Oksenhendler E, et al:Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280, 1995.
PubMed
7) Frizzera G:Castleman's disease and related disorders. Semin Diagn Pathol 5:346-364, 1988.
 
8) Fajgenbaum DC, van Rhee F, Nabel CS:HHV-8-negative, idiopathic multicentric Castleman disease:novel insights into biology, pathogenesis, and therapy. Blood 123:2924-2933, 2014.
PubMed
9) 高井和江, 新國公司, 渋谷宏行ほか:発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51:320-325, 2010.
 
10) Iwaki N, Fajgenbaum DC, Nabel CS, et al:Clinicopath-ologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castle-man disease. Am J Hematol 91:220-226, 2016.
 
11) Fajgenbaum DC, Uldrick TS, Bagg A, et al:Interna-tional, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129:1646-1657, 2017.
 
12) Yoshizaki K:A reference guide for management of Castleman disease. Rinsho Ketsueki 58:97-107, 2017.
PubMed
13) Fujimoto S, Koga T, Kawakami A, et al:Tentative diagnostic criteria and disease severity classification for Castleman disease:A report of the research group on Castleman disease in Japan. Mod Rheumatol 28:161-167, 2018.
 
14) Yoshizaki K, Matsuda T, Nishimoto N, et al:Pathogenic significance of interleukin-6(IL-6/BSF-2)in Castleman's disease. Blood 74:1360-1367, 1989.
PubMed
15) Nishimoto N, Kishimoto T:Interleukin 6:from bench to bedside. Nat Clin Pract Rheumatol 2:619-626, 2006.
PubMed
16) Miho Murakami, Takeshi Johkoh, Seiji Hayashi, et al:Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan. Mod Rheumatol 30:843-851, 2020.
PubMed
17) Koga T, Fujimoto S, Kawakami A et al:Therapeutic outlook for Castleman's disease:Prospects for the next decade. Expert Opinion on Orphan Drugs 5:633-640, 2017.
 
18) Nishimoto N, Kanakura Y, Aozasa K, et al:Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627-2632, 2005.
PubMed
19) van Rhee F, Voorhees P, Dispenzieri A, et al:International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132:2115-2124, 2018.
PubMed
20) Liu AY, Nabel CS, Finkelman BS, et al:Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol 3:e163-175, 2016.
PubMed
21) van Rhee F, Greenway A, Stone K. Treatment of Idiopathic Castleman Disease. Hematol Oncol Clin North Am 32:89-106, 2018.
PubMed
22) Akiyama M, Yasuoka H, Takeuchi T:Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab. Ann Hematol 96:2117-2119, 2017.
PubMed
23) Kawabata H, Kadowaki N, Nishikori M, et al:Clinica Features and Treatment of Multicentric Castleman's Disease:A Retrospective Study of 21 Japanese Patients at a Single Institute. J Clin Exp Hematop 53:69-77, 2013.
 
P.131 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al:2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1-11, 2013.
 
2) 日本循環器学会:血管炎症候群の診療ガイドライン(2008年版)(https://www.j-circ.or.jp/old/guideline/pdf/JCS2008_ozaki_h.pdf)
 
3) 日本循環器学会:血管炎症候群の診療ガイドライン(2017年改訂版)(http://www.j-circ.or.jp/guideline/pdf/JCS2017isobe_h.pdf)
 
4) Salvarani C, Pipitone N, Versari A, et al:Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 8:509-521, 2012.
PubMed
5) Robson JC, Kiran A, Maskell J, et al:The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis 74:129-135, 2015.
PubMed
6) Sugihara T, Hasegawa H, Uchida HA, et al:Associated factors of poor treatment outcomes in patients with giant cell arteritis:clinical implication of large vessel lesions. Arthritis Res Ther 22:72, 2020.
PubMed
7) Yates M, Loke YK, Watts RA, et al:Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis:meta-analysis. Clin Rheumatol 33:227-236, 2014.
 
8) Jover JA, Hernandez-Garcia C, Morado IC, et al: Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106-114, 2001.
PubMed
9) Mahr AD, Jover JA, Spiera RF, et al:Adjunctive methotrexate for treatment of giant cell arteritis:an individual patient data meta-analysis. Arthritis Rheum 56:2789-2897, 2007.
PubMed
10) Hoffman GS, Cid MC, Rendt-Zagar KE, et al:Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis:a randomized trial. Ann Intern Med 146:621-630, 2007.
PubMed
11) Seror R, Baron G, Hachulla E, et al:Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 73:2074-2081, 2014.
PubMed
12) Noris M, Daina E, Gamba S, et al:Interleukin-6 and RANTES in Takayasu arteritis:a guide for therapeutic decisions? Circulation 100:55-60, 1999.
PubMed
13) Park MC, Lee SW, Park YB, et al:Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology(Oxford)45:545-548, 2006.
PubMed
14) Roche NE, Fulbright JW, Wagner AD, et al:Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36:1286-1294, 1993.
PubMed
15) Weyand CM, Fulbright JW, Hunder GG, et al:Treatment of giant cell arteritis:interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 43:1041-1048, 2000.
PubMed
16) Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al:Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 58:1197-1200, 2008.
PubMed
17) Salvarani C, Magnani L, Catanoso M, et al:Tocilizumab:a novel therapy for patients with large-vessel vasculitis. Rheumatology 51:151-156, 2012.
PubMed
18) Seitz M, Reichenbach S, Bonel HM, et al:Rapid induction of remission in large vessel vasculitis by IL-6 blockade. Swiss Med Wkly 141:2011.
PubMed
19) Unizony S, Arias-Urdaneta L, Miloslavsky E, et al:Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis)and polymyalgia rheumatica. Arthritis Care Res 64:1720-1729, 2012.
PubMed
20) Nakaoka Y, Higuchi K, Arita Y, et al:Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J 54:405-411, 2013.
PubMed
21) Nakaoka Y, Isobe M, Takei S, et al:Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis:results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan(the TAKT study). Ann Rheum Dis 77:348-354, 2018.
PubMed
22) Nakaoka Y, Isobe M, Tanaka Y, et al:Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis:final results of the randomized controlled phase 3 TAKT study. Rheumatology 59:2427-2434, 2020.
PubMed
23) Villiger PM, Adler S, Kuchen S, et al:Tocilizumab for induction and maintenance of remission in giant cell arteritis:a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921-1927, 2016.
PubMed
24) Stone JH, Tuckwell K, Dimonaco S, et al:Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 377:317-328, 2017.
PubMed
25) Strand V, Dimonaco S, Tuckwell K, et al:Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. Arthritis Res Ther 21:64, 2019.
 
26) Muratore F, Salvarani C:Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab. Ann Rheum Dis 2019 APR 16:Annrheumdius-2019-215459.
 
27) Sanchez-Alvarez C, Koster M, Duarte-Garcia A, et al:Disease progression of Takayasu arteritis in two patients treated with tocilizumab. Ann Rheum Dis 79:e21, 2020.
 
28) Arita Y, Nakaoka Y, Eda Y, et al:Perioperative Management of Takayasu Arteritis for Cardiac Surgery in a Patient Treated With Tocilizumab. JACC Case Reports. J Am Coll Cordiol Case Rep 2(15):2366-2367, 2020.
 
29) Arita Y, Nakaoka Y, Otsuki M, et al:Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis. Int J Cardiol 187:319-321, 2015.
 
P.137 掲載の参考文献
1) Pedersen SJ, Maksymowych WP:The Pathogenesis of Ankylosing Spondylitis:an Update. Curr Rheumatol Rep 21(58):4-10, 2019.
 
2) Schett G, R Lories RJ, D'Agostino M, et al:Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 13:731-741, 2017.
 
3) McGonagle DG, McInnes IB, Kirkham BW, et al:The role of IL-17A in axial spondyloarthritis and psoriatic arthritis:recent advances and controversies. Ann Rheum Dis 78:1167-1178, 2019.
PubMed
4) Gossec L, Baraliakos X, Kerschbaumer A, et al:EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies:2019 update. Ann Rheum Dis 79:700-712, 2020.
PubMed
5) Coates LC, Kavanaugh A, Mease PJ, et al:Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 68:1060-1071, 2016.
 
6) Mease P, van der Heijde D, Landewe R, et al:Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression:primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 77:890-897, 2018.
PubMed
7) Chandran V, van der Heijde D, Fleischmann RM, et al:Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial(SPIRIT-P1). Rheumatology(Oxford)59 (10):2774-2784, 2020.
PubMed
8) McInnes IB, Behrens F, Mease PJ, et al:Secukinumab versus adalimumab for treatment of active psoriatic arthritis(EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 395(10235):1496-1505, 2020.
PubMed
9) Smolen JS, Mease P, Tahir H, et al:Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug:final results by week 52. Ann Rheum Dis 79:1310-1319, 2020.
 
10) Ward MM, Deodhar A, Gensler LS, et al:2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 71:1599-1613, 2019.
PubMed
11) Dougados M, Wei JC, Landewe R, et al:Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis(COAST-V and COAST-W). Ann Rheum Dis 79:176-185, 2020.
PubMed
12) Maksymowych WP, Strand V, Nash P, et al:Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. Eur J Rheumatol 5:216-223, 2018.
PubMed
13) Haroon M, Gallagher P, FitzGerald O:Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 74:1045-1050, 2015.
PubMed
14) Ramiro S, van der Heijde D, van Tubergen A, et al:Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis:12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 73:1455-1461, 2014.
PubMed
15) Sari I, Haroon N:Radiographic Progression in Ankylosing Spondylitis: From Prognostication to Disease Modification. Curr Rheumatol Rep 20:82, 2018.
PubMed
16) Poddubnyy D, Haibel H, Listing J, et al:Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis:results from the GErman SPondyloarthritis Inception Cohort(GESPIC). Ann Rheum Dis 72:1430-1432, 2013.
 
17) Schreiber S, Colombel JF, Feagan BG, et al:Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 78:473-479, 2019.
PubMed
18) van der Linden S, Valkenburg HA, Cats A. et al: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368, 1984.
PubMed
19) M Rudwaleit, D van der Heijde, R Landewe, et al:The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis(part II):validation and final selection. Ann Rheum Dis 68:777-783, 2009.
 
20) Oton T, Sastre C, Carmona L:The journey of the non-radiographic axial spondyloarthritis patient:the perspective of professionals and patients. Clin Rheumatol 2020 Jul 6. doi:10.1007/s10067-020-05269-z, 2020.
 
21) X線基準を満たさない体軸性脊椎関節炎. 脊椎関節炎診療の手引き2020. 日本脊椎関節炎学会・厚生労働科学研究費補助金(難治性疾患政策研究事業)「強直性脊椎炎に代表される脊椎関節炎の疫学調査・診断基準作成と診療ガイドライン策定を目指した大規模多施設研究」班編. 診断と治療社, 東京. p43-45, 2020.
 
P.144 掲載の参考文献
1) Pappu R, Rutz S, Ouyang W:Regulation of epithelial immunity by IL-17 family cytokines. Trends Immunol 33:343-349, 2012.
PubMed
2) Miossec P, Kolls JK:Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11:763-776, 2012.
PubMed
3) Martin DA, Towne JE, Kricorian G, et al:The emerging role of IL-17 in the pathogenesis of psoriasis:preclinical and clinical findings. J Invest Dermatol 133:17-26, 2013.
PubMed
4) Korn T, Bettelli E, Oukka M, et al:IL-17 and Th17 Cells. Annu Rev Immunol 27:485-517, 2009.
PubMed
5) Johansen C, Riis JL, Gedebjerg A, et al:Tumor necrosis factor α-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor κB. J Biol Chem 286:25487-25494, 2011.
 
6) Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al:Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131:677-687, 2011.
 
7) Krueger JG, Fretzin S, Suarez-Farinas M, et al:IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 130:145-154, 2012.
PubMed
8) Kammuller M, Tsai TF, Griffiths CE, et al:Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology 6:e152, 2017.
PubMed
9) Blauvelt A, Reich K, Tsai T-F, et al:Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year:Results from the CLEAR study. J Am Acad Dermatol 76:60-69, 2017.
PubMed
10) Bissonnette R, Luger T, Thaci D, et al:Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment(SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 32:1507-1514, 2018.
 
11) Spindeldreher S, MaillereB, Correia E, et al:Secuki-numab Demonstrates Significantly Lower Immunoge-nicity Potential Compared to Ixekizumab. Dermatol Ther(Heidelb)8:57-68, 2018.
 
12) Reich K, Blauvelt A, Armstrong A, et al:Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol 33:1733-1741, 2019.
PubMed
13) Blauvelt A, Reich K, Warren RB, et al:Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. Br J Dermatol 177:879-881, 2017.
PubMed
14) Bagel J, Duffin KC, Moore A, et al:The effect of secukinumab on moderate-to-severe scalp psoriasis:Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol 77:667-674, 2017.
PubMed
15) Reich K, Sullivan J, Arenberger P, et al:Effect of secukinumab on the clinical activity and disease burden of nail psoriasis:32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol 181:954-966, 2019.
PubMed
16) Leonardi C, Reich K, Foley P, et al:Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatol Ther(Heidelb)10:431-447, 2020.
PubMed
17) Paul C, Griffiths CE, van de Kerkhof PCM, et al:Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. J Am Acad Dermatol 80:70-79. e3, 2019.
 
18) Blauvelt A, Papp K, Gottlieb A, et al:A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis:12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol 182:1348-1358, 2020.
 
19) Blauvelt A, Leonardi C, Elewski B, et al:A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis:24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol doi: 10.1111/bjd.19509, 2020(Online ahead of print).
 
20) Ryan C, Menter A, Guenther L, et al:Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol 179:844-852, 2018.
 
21) Puig L, Lebwohl M, Bachelez H, et al:Long-term efficacy and safety of brodalumab in the treatment of psoriasis:120-week results from the randomized, double-blind, placebo-and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol 82:352-359, 2020.
 
22) Umezawa Y, Nakagawa H, Niiro H, et al:Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 30: 1957-1960, 2016.
PubMed
23) Menter A, Strober BE, Kaplan DH, et al:Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80:1029-1072, 2019.
PubMed
24) Elmets CA, Leonardi CL, Davis DMR, et al:Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 80:1073-1113, 2019.
PubMed
25) Ishigame H, Kakuta S, Nagai T, et al:Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses.Immunity 30:108-119, 2009.
PubMed
26) Conti HR, Shen F, Nayyar N, et al:Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206:299-311, 2009.
PubMed
27) McDonald DR:TH17 deficiency in human disease. J Allergy Clin Immunol 129:1429-1435, 2012.
 
28) Chijiwa C, Takeoka S, Kamata M, et al:Secukinumab decreases serum Krebs von den Lungen 6(KL-6)level in patients with psoriasis with elevated serum KL-6 level. Br J Dermatol 179:1396-1397, 2018.
 
29) Elnabawi YA, Dey AK, Goyal A, et al:Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res 115:721-728, 2019.
PubMed
30) Ikumi K, Odanaka M, Shime H:Is Associated with Psoriatic Inflammation in Both Humans and Mice. J Invest Dermatol 139:1329-1338, 2019.
PubMed
31) Blauvelt A, Papp KA, Merola JF, et al:Bimekizumab for patients with moderate to severe plaque psoriasis:60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol 83:1367-1374, 2020.
PubMed
P.153 掲載の参考文献
1) 大久保ゆかり, 荒井佳恵, 藤原尚子ほか:Skindex-16/GHQ-28を用いた乾癬患者に対するQOL評価と治療満足度調査. 日皮会誌 117:2495-2505, 2007.
 
2) Nestle FO, Conrad C, Tun-Kyi A, et al:Plasmacytoid predendritic cells iniciate psoriasis through interferon-alpha production. J Exp Med 202:135-143, 2005.
 
3) Trinchieri G:Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146, 2003.
PubMed
4) Michele WLT, Edward PB, Joshua JM, et al:IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat med 21:719-729, 2015.
 
5) Igarashi A, Kato T, Kato M, et al:Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis:long-term results from a phase 2/3 clinical trial. J Dermatol 39:242-252, 2012.
PubMed
6) Ohtsuki M, Kubo H, Morishima H, et al:Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients:Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol 45:1053-1062, 2018.
PubMed
7) Terui T, Kobayashi S, Okubo Y, et al:Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis:a phase 3 randomized clinical trial. JAMA Dermatol 155:1153-1161, 2019.
PubMed
8) Gordon KB, Strober B, Lebwohl M, et al:Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis(UltIMMa-1 and UltIMMa-2):results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 392:650-661, 2018.
PubMed
9) Reich K, Papp KA, Blauvelt A, et al:Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis(reSURFACE 1 and reSURFACE 2):results from two randomised controlled, phase 3 trials. Lancet 390:276-288, 2017.
PubMed
10) Reich k, Warren RB, Iversen L, et al:Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis:pooled analyses of two randomized phase III clinical trials(reSURFACE 1 and reSURFACE 2)through 148 weeks. Br J Dermatol 182:605-617, 2020.
 
11) 日本皮膚科学会乾癬生物学的製剤検討委員会:乾癬における生物学的製剤の使用ガイダンス(2019年版). 日皮会誌 129:1845-1864, 2019.
 
12) Ohtsuki M, Terui T, Ozawa A, et al:Japanese guidanace for use of biologics for psoriasis(the 2013 version). J Dermatol 40:683-695, 2013.
PubMed
13) Hiruma J, Harada K, Hirayama M, et al:Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infections. J Derm Sci 101:145-146, 2021.
 
14) Tasaka S, Tokuda H:Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 18:793-806, 2012.
PubMed
15) Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al:Interstitial lung disease induced or exacerbated by TNF targeted therapies:analysis of 122 cases. Semin Arthritis Rheum 41:256-264, 2011.
 
16) Matsumoto Y, Abe N, Tobita R, et al:The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis. J Clin Exp 45:853-858, 2020.
 
17) Okubo Y, Tsuruta D, Tang AC, et al:Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. J Eur Acad Dermatol Venereol 32:606-614, 2018.
PubMed
P.157 掲載の参考文献
1) Benson JM, Sachs CW, Treacy G, et al:Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol 29:615-624, 2011.
PubMed
2) Dillon SB:New mechanisms and expanded indica-tions for biologic therapies:a perspective on immunology research and development. Drug Disc World Fall:87-93, 2010.
 
3) Leonardi CL, Kimball AB, Papp KA, et al:Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial(PHOENIX 1). Lancet 371:1655-1674, 2008.
 
4) McInnes IB, Kavanaugh A, Gottlieb AB, et al:Efficacy and safety of ustekinumab in patients with active psoriatic arthritis:1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780-789, 2013.
PubMed
5) Araujo EG, Englbrecht M, Hoepken S, et al:Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis(ECLIPSA)study. Semin Arthritis Rheum 48:632-637, 2018.
PubMed
6) Egeberg A, Ottosen MB, Gniadecki R, et al:Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 178:509-519, 2018.
PubMed
P.164 掲載の参考文献
1) Baumgart DC, Sandborn WJ:Crohn's disease. Lancet 380:1590-1605, 2012.
PubMed
2) 中村好一:厚生労働科学研究費補助金 難治性疾患政策研究事業(難治性疾患の継続的な疫学データの収集・解析に関する研究)分担研究報告書.
 
3) Graham DB, . Xavier RJ:Pathway paradigms revealed from the genetics of inflammatory bowel disease, Nature 578:527-539, 2020.
PubMed
4) Manichanh C, Borruel N, Casellas F, et al:The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9 (10):599-608, 2012.
PubMed
5) Larabi A, Barnich N, Nguyen HTT:New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy 16(1):38-51, 2020.
PubMed
6) Teratani T, Mikami Y, Nakamoto N, et al:The liver-brain-gut neural arc maintains the Treg cell niche in the gut. Nature 585(7826):2020.
PubMed
7) Ben-Horin S, Chowers Y:Review article:Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 33(9):987-995, 2011.
PubMed
8) Schmitt H, Billmeier U, Dieterich W, et al:Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut 68(5):814-828, 2018.
PubMed
9) Benson JM, Peritt D, Scallon BJ, et al:Discovery and mechanism of ustekinumab:a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 3(6):535-545, 2011.
PubMed
10) Neurath MF:Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 14(5):269-278, 2017.
PubMed
11) Eftychi C, Schwarzer R, Vlantis K, et al:Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment. Immunity 51(2):367-380. e4, 2019.
 
12) Sandborn WJ, Gasink C, Gao L-L, et al:Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease. N Engl J Med 367(16):1519-1528, 2012.
PubMed
13) Hanauer SB, Sandborn WJ, Fegan BG, et al:IM-UNITI:Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis 14(1):23-32, 2020.
 
14) Rutgeerts P, Gasink C, Chan D, et al:Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology 155 (4):1045-1058, 2018.
PubMed
15) Lee MJ, Parker CE, Taylor SR, et al:Efficacy of Medical Therapies for Fistulizing Crohn's Disease:Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 16(12):1879-1892, 2018.
PubMed
16) Kopylov U, Hanzel J, Liefferinckx C, et al:Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Aliment Pharmacol Ther 52(1):135-142, 2020.
PubMed
17) Murate K, Maeda K, Nakamura M, et al:Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients. Inflamm Bowel Dis 26(11):1669-1681, 2020.
 
18) Sandborn WJ, Gasink C, Gao L-L, et al:Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease. N Engl J Med 367(16):1519-1528, 2012.
PubMed
19) Singh S, Fumery M, Sandborn WJ, et al:Systematic review and network meta-analysis:first-and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther 48(4):394-409, 2018.
PubMed
20) Loftus EV, Sloan S, Ramachandran P, et al:Comparison of rates of active tuberculosis infection in the phase 2 and 3 clinical trial programs for antiIL12/23 and anti-TNFS. Gastroenterology 152:S596, 2017.
 
21) Gerosa M, Argolini LM, Artusi C, et al:The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol 11(10):987-998, 2018.
PubMed
22) AlAmeel T, Al Sulais E:Ustekinumab and Pregnancy:Continue or Cease Before You Conceive? Gastroenterol-ogy 157(5):1435, 2019.
PubMed
23) Weizman AV, Nguyen GC, Seow CH, et al:Ap-propriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. Inflamm Bowel Dis 25(2):328-335, 2019.
 
24) Iwamoto M, Kato K, Moriyama M:Elderly-onset Crohn's disease remarkably responsive to ustekinumab:a case report. Int J Colorectal Dis 35(2):355-359, 2020.
PubMed
25) Olbjorn C, Rove JB, Jahnsen J:Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease:A Case Series and Review of the Literature. Pediatr Drugs 22(4):409-416, 2020.
 
26) Torres J, Bonovas S, Doherty, et al:ECCO Guidelines on Therapeutics in Crohn's Disease:Medical Treatment. J Crohns Colitis 14(1):4-22, 2020.
PubMed
27) Tillack C, Ehmann LM, Friedrich M, et al:Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63(4):567-577, 2014.
 
28) Murate K, Nakamura M, Fujishiro M:A Case Where Administration of Ustekinumab Maintained the Intestinal Patency after Balloon Dilation for Small Intestinal Stenosis Caused by Crohn's Disease. Inflamm Bowel Dis 25(11):e140, 2019.
 
29) Peyrin-Biroulet L, Loftus EV, Colombel JF, et al:The natural history of adult crohn's disease in population-based cohorts. Am J Gastroenterol 105(2):289-297, 2010.
PubMed
30) Latella G, Papi C:Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol 18(29):3790-3799, 2012.
PubMed
31) Mascheretti S, Hampe J, Kuhbacher T, et al:Pharmaco-genetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2(2):127-136, 2002.
 
32) Steinhart AH, Bitton A, Griffiths A, et al:A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804):1461-1463, 2006.
 
P.169 掲載の参考文献
1) McInnes IB, Schett G:The pathogenesis of rheumatoid arthritis.N Engl J Med 365(23):2205-2209, 2011.
PubMed
2) Raj T, Rothamel K, Mostafavi S, et al:Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344:519-523, 2014.
PubMed
3) Smolen JS, Burmester GR, Dougados M, et al:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2019 update. Ann Rheum Dis 79(6):685-699, 2020.
PubMed
4) 日本リウマチ学会:関節リウマチ(RA)に対するアバタセプト使用の手引き(2020年2月1日改訂版).https://www.ryumachi-jp.com/publish/guide/guideline_tnf/
 
5) Westhovens R, Kremer JM, Moreland LW, et al:Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 36(4):736, 2009.
PubMed
6) Schiff M, Weinblatt ME, Valente R, et al:Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73:86-94, 2014.
PubMed
7) Courvoisier DS, Chatzidionysiou K, Mongin D, et al:The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents:results from a collaboration of 16 registries. Rheumatology 60(2):820-828, 2021.(published online Aug 18.)https://doi.org/10.1093/rheumatology/keaa393
 
8) Kurata I, Tsuboi H, Terasaki M, et al:Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis. Intern Med 58:1703-1712, 2019.
PubMed
9) Tsuboi H, Matsumoto I, Hagiwara S, et al:Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study:ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy)trial. Mod Rheumatol 26(6):891-899, 2016.
PubMed
P.176 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al:2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1-11, 2013.
 
2) 厚生労働省補助事業 難病医学研究財団 難病情報センター:AAV3 疾患診断基準(43.顕微鏡的多発血管炎, 44.多発血管炎性肉芽腫症, 45.好酸球性多発血管炎性肉芽腫症)(https://www.nanbyou.or.jp/entry/5346#001)
 
3) Watts R, Lane S, Hanslik T, et al:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.Ann Rheum Dis 66:222-227, 2007.
PubMed
4) Stone JH, Merkel PA, Spiera R, et al:Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221-232, 2010.
PubMed
5) Jones RB, Tervaert JW, Hauser T, et al:Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211-220, 2010.
PubMed
6) 厚生労働科学研究費補助金難治性疾患等政策研究事業 難治性血管炎に関する調査研究班 有村義宏・難治性腎疾患に関する調査研究班 丸山彰一・びまん性肺疾患に関する調査研究班 本間栄編. ANCA 関連血管炎診療ガイドライン 2017. 診断と治療社, 東京. 2017.
 
7) Terrier B, Charles P, Aumaitre O, et al;French Vasculitis Study Group:ANCA-associated vasculitides:Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance. Presse Med 49:104031, 2020.
 
8) 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)難治性腎障害に関する調査研究班編:エビデンスに基づく急速進行性腎炎症候群 RPGN診療ガイドライン2020. 東京医学社, 東京. 2020.
 
9) 日本循環器学会:血管炎症候群の診療ガイドライン(2017年改訂版)(https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_isobe_h.pdf)
 
10) Smith RM, Jones RB, Specks U, et al;RITAZAREM coinvestigators:Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 79:1243-1249, 2020.
PubMed
11) Guillevin L, Pagnoux C, Karras A, et al;French Vasculitis Study Group:Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771-1780, 2014.
 
12) Charles P, Terrier B, Perrodeau E, et al;French Vasculitis Study Group:Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77:1143-1149, 2018.
 
13) Jayne DRW, Merkel PA, Schall TJ, et al;ADVOCATE Study Group:Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 384:599-609, 2021.
 
P.182 掲載の参考文献
1) Davin JC:The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol 31:207-215, 2016.
PubMed
2) Araya CE, Wasserfall CH, Brusko TM, et al:A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 21:603-610, 2006.
PubMed
3) Debiec H, Dossier C, Letouze E, et al:Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome. J Am Soc Nephrol 29:2000-2013, 2018.
PubMed
4) Jia X, Yamamura T, Gbadegesin R, et al:Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome. Kidney Int 98:1308-1322, 2020.
PubMed
5) Benz K, Dotsch J, Rascher W, et al:Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794-797, 2004.
 
6) Nozu K, Iijima K, Fujisawa M, et al:Rituximab treatment for posttransplant lymphoproliferative disorder(PTLD)induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660-1663, 2005.
PubMed
7) Iijima K, Sako M, Nozu K, et al:Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273-1281, 2014.
 
8) Ravani P, Rossi R, Bonanni A, et al:Rituximab in Children with Steroid-Dependent Nephrotic Syndrome:A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol 26:2259-2266, 2015.
PubMed
9) Colucci M, Carsetti R, Cascioli S, et al:B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. J Am Soc Nephrol 27:1811-1822, 2016.
PubMed
10) Fornoni A, Sageshima J, Wei C, et al:Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3:85ra46, 2011.
PubMed
11) Kim AH, Chung JJ, Akilesh S, et al:B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight 2:e81836, 2017.
PubMed
12) 難治性疾患政策研究事業「小児腎領域の希少・難治性疾患群の診療・研究体制の確立」(厚生労働科学研究費補助金):小児特発性ネフローゼ症候群診療ガイドライン2020. 日本小児腎臓病学会監修. 2020.
 
13) Hogan J, Dossier C, Kwon T, et al:Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 34:253-259, 2019.
 
14) Maxted AP, Dalrymple RA, Chisholm D, et al:Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatr Nephrol 34:855-863, 2019.
PubMed
15) Chan EY, Webb H, Yu E, et al:Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97:393-401, 2020.
PubMed
16) Ravani P, Magnasco A, Edefonti A, et al:Short-term effects of rituximab in children with steroid-and calcineurin-dependent nephrotic syndrome:a randomized controlled trial. Clin J Am Soc Nephrol 6:1308-1315, 2011.
PubMed
17) Kamei K, Ishikura K, Sako M, et al:Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32:2071-2078, 2017.
PubMed
18) Kamei K, Ishikura K:Rituximab treatment for refractory steroid-resistant nephrotic syndrome. Pediatr Nephrol 31:337-338, 2016.
PubMed
19) Kamei K, Ogura M, Sato M, et al:Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. Pediatr Nephrol 33:1013-1018, 2018.
PubMed
20) Kamei K, Takahashi M, Fuyama M, et al:Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome:case series and review of literature. Nephrol Dial Transplant 30:91-96, 2015.
PubMed
21) Fujinaga S, Tomii Y:Predictors of rituximab-related neutropenia in Japanese children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 34:1303-1304, 2019.
PubMed
22) Delbe-Bertin L, Aoun B, Tudorache E, et al:Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? Pediatr Nephrol 28:447-451, 2013.
PubMed
23) Bonanni A, Calatroni M, D'Alessandro M, et al:Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 84:1238-1249, 2018.
PubMed
24) 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)難治性腎障害に関する調査研究班:エビデンスに基づくネフローゼ症候群 診療ガイドライン2017. 難治性腎疾患に関する調査研究班編. 2017.
 
25) Wang CS, Liverman RS, Garro R, et al:Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol 32:835-841, 2017.
PubMed
26) Basu B:Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med 370:1268-1270, 2014.
PubMed
27) Bonanni A, Rossi R, Murtas C, et al:Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. BMJ Case Rep 2015:2015.
PubMed
P.188 掲載の参考文献
1) Lucchini E, Zaja F, Bussel J:Rituximab in the treatment of immune thrombocytopenia:what is the role of this agent in 2019? Haematologica 104(6):1124-1135, 2019.
PubMed
2) Kashiwagi H, Kuwana M, Hato T, et al:Reference guide for management of adult immune thrombocyto-penia in Japan:2019 Revision. International Journal of Hematology 111(3):329-351, 2020.
 
3) Miyakawa Y, Katsutani S, Yano T, et al:Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy. International Journal of Hematology 102(6):654-661, 2015.
PubMed
4) Zaja F, Vianelli N, Volpetti S, et al:Low-dose rituximab in adult patients with primary immune thrombocytopenia. European Journal of Haematology 85(4):329-334, 2010.
PubMed
5) Tran H, Brighton T, Grigg A, et al:A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura(R-ITP1000 study). British Journal of Haematology 167(2):243-251, 2014.
PubMed
6) Stasi R, Pagano A, Stipa E, et al:Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98(4):952-957, 2001.
PubMed
7) Godeau B, Porcher R, Fain O, et al:Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:results of a prospective multicenter phase 2 study. Blood 112 (4):999-1004, 2008.
PubMed
8) Khellaf M, Charles-Nelson A, Fain O, et al:Safety and efficacy of rituximab in adult immune thrombocytope-nia: results from a prospective registry including 248 patients. Blood 124(22):3228-3236, 2014.
 
9) Arnold DM, Dentali F, Crowther MA, et al:Systematic review:efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of Internal Medicine 146(1):25-33, 2007.
PubMed
10) Cooper N, Stasi R, Cunningham-Rundles S, et al: The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology 125(2):232-239, 2004.
PubMed
11) Zaja F, Baccarani M, Mazza P, et al:Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115(14):2755-2762, 2010.
PubMed
12) Choi PY, Roncolato F, Badoux X, et al:A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine(TT4). Blood 126 (4):500-503, 2015.
PubMed
13) Gomez-Almaguer D, Colunga-Pedraza PR, Gomez-De Leon A, et al:Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia. British Journal of Haematology 184(2):288-290, 2019.
PubMed
14) Marangon M, Vianelli N, Palandri F, et al:Rituximab in immune thrombocytopenia:gender, age, and response as predictors of long-term response. European Journal of Haematology 98(4):371-377, 2017.
PubMed
15) Hasan A, Michel M, Patel V, et al:Repeated courses of rituximab in chronic ITP:Three different regimens. American Journal of Hematology 84(10):661-665, 2009.
PubMed
16) Bussel JB, Lee CS, Seery C, et al:Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica 99(7):1264-1271, 2014.
PubMed
17) Chapin J, Lee CS, Zhang H, et al:Gender and duration of disease differentiate responses to rituximab-dexa-methasone therapy in adults with immune thrombocy-topenia. American Journal of Hematology 91(9):907-911, 2016.
 
18) 田中靖人, 楠本茂:免疫抑制剤使用時の肝炎ウイルス再活性化. 日本内科学会雑誌 10(7):1645-1653, 2014.
 
19) Chugh S, Darvish-Kazem S, Lim W, et al:Rituximab plus standard of care for treatment of primary immune thrombocytopenia:a systematic review and meta-analysis. The Lancet Haematology 2(2):e75-81, 2015.
PubMed
20) Carson KR, Evens AM, Richey EA, et al:Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients:a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20):4834-4840, 2009.
PubMed
P.194 掲載の参考文献
1) Wallace DJ, Stohl W, Furie RA, et al:A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61:1168-1178, 2009.
PubMed
2) Luijten KMAC, Tekstra J, Bijlsma JWJ, et al:The Systemic Lupus Erythematosus Responder Index(SRI); A new SLE disease activity assessment. Autoimmun Rev 11:326-329, 2012.
 
3) Navarra SV, Guzman RM, Gallacher AE, et al:Efficacy and safety of belimumab in patients with active systemic lupus erythematosus:a randomised, placebo-controlled, phase 3 trial. Lancet 377:721-731, 2011.
PubMed
4) Furie R, Petri M, Zamani O, et al:A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients With Systemic Lupus Erythematosus. Arthritis Rheum 63:3918-3930, 2011.
PubMed
5) Stohl W, Schwarting A, Okada M, et al:Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus:A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheum 69:1016-1027, 2017.
 
6) 全身性エリテマトーデス診療ガイドライン 2019. 厚生労働科学研究費補助金難治性疾患等制作政策事業 自己免疫疾患に関する調査研究(自己免疫班)・日本リウマチ学会編. 南山堂, 東京. 2019年.
 
7) Fanouriakis A, Kostopoulou M, Alunno A, et al:2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736-745, 2019.
PubMed
8) Dooley MA, Houssiau F, Aranow C, et al:Effect of belimumab treatment on renal outcomes:results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22:63-72, 2013.
PubMed
9) Furie R, Rovin BH, Houssaiu F, et al:Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New Engl J Med 383:12, 2020.
PubMed
10) Merrill JT, Neuwelt CM, Wallace DJ, et al:Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222-233, 2010.
PubMed
11) Rovin BH, Furie R, Latinis K, et al:Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215-1226, 2012.
PubMed
12) Ryden-Aulin M, Boumpas D, Bultink I, et al:Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med 3:e000613, 2016.
 
P.202 掲載の参考文献
1) 日本リウマチ学会:若年性特発性関節炎初期診療の手引き. 日本リウマチ学会小児リウマチ調査検討小委員会編. メディカルレビュー社, 東京. 2015.
 
2) Petty RE, Southwood TR, Manners P, et al: International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis:Second Revision, Edmonton 2001. J Rheumatol 31:390-392, 2004.
PubMed
3) 横田俊平, 今川智之, 武井修治ほか:若年性特発性関節炎に対する生物学的製剤治療の手引き(2008)I.トシリズマブ. 日本小児科学会雑誌 112:911-923, 2008.
 
4) 日本小児リウマチ学会 ガイドライン作成委員会:市販後調査のための全身型若年性特発性関節炎に対するカナキヌマブ使用の手引き. 小児リウマチ 9:88-92, 2018.
 
5) Lee JJY, Schneider R:Systemic Juvenile Idiopathic Arthritis. Pediatr Clin North Am 65:691-709, 2018.
PubMed
6) Martini A:Systemic juvenile idiopathic arthritis. Autoimmun Rev 12:56-59, 2012.
PubMed
7) Mellins ED, Macaubas C, Grom AA:Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 7:416-426, 2011.
PubMed
8) 武井修治:平成26年度 厚生労働化学研究費補助金(成育疾患克服等次世代育成基盤研究事業 健やか次世代育成総合研究事業)「今後の小児慢性特定疾患治療研究事業のあり方に関する研究」分担研究報告書 生物学的製剤による治療がもたらした若年性特発性関節炎 JIAの臨床病態の変化.
 
9) 若年性特発性関節炎における生物学的製剤使用の手引き2020年版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 小児期および成人移行期小児リウマチ患者の全国調査データの解析と両者の異同性に基づいた全国的「シームレス」診療ネットワーク構築による標準的治療の均てん化研究班 若年性特発性関節炎分担班編. 羊土社, 東京. 2020.
 
10) Ruperto N, Brunner HI, Quatier P, et al:Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2396-2406, 2012.
 
11) Ruperto N, Brunner HI, Quatier P, et al:Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis 77:1710-1719, 2018.
 
12) Nishimura K, Hara R , Umebayashi H, et al:Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients. Mod Rheumatol 31:226-234, 2021.
PubMed
13) Mellins ED, Macaubas C, Grom AA:Pathogenesis of systemic juvenile idiopathic arthritis:some answers, more questions. Nat Rev Rheumatol 7:416-426, 2011.
PubMed
14) Yokota S, Itoh Y, Morio T, et al:Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 75:1654-1660, 2016.
 
15) De Benedetti F, Brunner HI, Ruperto N, et al:Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. N Engl J Med 367:2385-2395, 2012.
PubMed
16) Grom AA, Ilowite NT, Pascual V, et al:Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol 68: 218-228, 2016.
PubMed
17) Ravelli A, Minoia F, Davi S, et al:2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American college of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 68:566-576, 2016.
PubMed
18) Shimizu M, Mizuta M, Yasumi T, et al:Validation of Classification Criteria of Macrophage Activation Syndrome in Japanese Patients With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res 70:1412-1415, 2018.
PubMed
19) Schulert GS, Minoia F, Bohnsack J, et al:Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res 70:409-419, 2018.
PubMed
20) Shimizu M, Nakagishi Y, Kasai K, et al:Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome:the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 58:287-294, 2012.
PubMed
21) Ringold S, Weiss PF, Beukelman T, et al:2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499-2512, 2013.
PubMed
P.211 掲載の参考文献
1) Kastner DL, Aksentijevich I, Goldbach-Mansky R:Autoinflammatory disease reloaded:a clinical perspective. Cell 140:784-790, 2010.
PubMed
2) Masters SL, Simon A, Aksentijevich I, et al:Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease(*). Annu Rev Immunol 27:621-668, 2009
PubMed
3) de Jesus AA, Canna SW, Liu Y, et al:Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol 33:823-874, 2015.
PubMed
4) Migita K, Uehara R, Nakamura Y, et al:Familial Mediterranean fever in Japan. Medicine(Baltimore) 91:337-343, 2012.
PubMed
5) Migita K, Izumi Y, Jiuchi Y, et al:Familial Mediterranean fever is no longer a rare disease in Japan. Arthritis Res Ther 18:175, 2016.
PubMed
6) Ueda N, Ida H, Washio M, et al:Clinical and genetic features of patients with TNFRSF1A variants in Japan:findings of a nationwide survey. Arthritis Rheumatol 68:2760-2771, 2016.
PubMed
7) van der Hilst JC, Bodar EJ, Barron KS, et al:Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine(Baltimore)87:301-310, 2008.
 
8) Bader-Meunier B, Florkin B, Sibilia J, et al:Mevalonate kinase deficiency:a survey of 50 patients. Pediatrics 128:e152-159, 2011.
PubMed
9) Schroder K, Tschopp J:The inflammasomes. Cell 140 (6):821-832, 2010.
PubMed
10) Davis BK, Wen H, Ting JP:The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29:707-735, 2011.
PubMed
11) Dinarello CA:The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol 15:612-632, 2019.
PubMed
12) Bettiol A, Lopalco G, Emmi G, et al:Unveiling the effi-cacy, safety, and tolerability of anti-interleukin-1 treat-ment in monogenic and multifactorial autoinflammatory diseases. Int J Mol Sci 20:1898, 2019.
 
13) Hoffman HM:Therapy of autoinflammatory syndromes. J Allergy Clin Immunol 124:1129-1138, 2009.
PubMed
14) Caorsi R, Federici S, Gattorno M:Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 12:81-86, 2012.
PubMed
15) Soriano A, Soriano M, Espinosa G, et al:Current therapeutic options for the main monogenic autoinflammatory diseases and PFAPA syndrome:evidence-based approach and proposal of a practical guide. Front Immunol 11:865, 2020.
PubMed
16) Goldbach-Mansky R, Dailey NJ, Canna SW, et al:Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581-592, 2006.
PubMed
17) Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al:Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 63:840-849, 2011.
PubMed
18) Hoffman HM, Throne ML, Amar NJ, et al:Efficacy and safety of rilonacept(interleukin-1 Trap)in patients with cryopyrin-associated periodic syndromes:results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443-2452, 2008.
PubMed
19) Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al:Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360:2416-2425, 2009.
PubMed
20) Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al:Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70:2095-2102, 2011.
PubMed
21) Brogan PA, Hofer M, Kuemmerle-Deschner JB, et al:Rapid and sustained long-term efficacy and safety of Canakinumab in patients with cryopyrin-associated periodic syndrome ages five years and younger. Arthritis Rheumatol 71:1955-1963, 2019.
PubMed
22) Yokota S, Imagawa T, Nishikomori R, et al:Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. Clin Exp Rheumatol 108:19-26, 2017.
 
23) Ozen S, Demirkaya E, Duzova A, et al:FMF50:a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 73:897-901, 2014.
PubMed
24) Ben-Zvi I, Kukuy O, Giat E, et al:Anakinra for colchicine-resistant familial Mediterranean fever:a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 69:854-862, 2017.
PubMed
25) Hashkes PJ, Spalding SJ, Giannini EH, et al:Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever:a randomized trial[published correction appears in Ann Intern Med. 160:291-292, 2014]. Ann Intern Med 157:533-541, 2012.
PubMed
26) Brik R, Butbul-Aviel Y, Lubin S, et al:Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever:a 6-month open-label, single-arm pilot study. Arthritis Rheumatol 66:3241-3243, 2014.
PubMed
27) De Benedetti F, Gattorno M, Anton J, et al:Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 378:1908-1919, 2018.
PubMed
28) Ozen S, Ben-Cherit E, Foeldvari I, et al:Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever:results from the randomised phase III CLUSTER trial. Ann Rheum Dis 79:1362-1369, 2020.
PubMed
29) Gattorno M, Pelagatti MA, Meini A, et al:Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58:1516-1520, 2008.
PubMed
30) Obici L, Meini A, Cattalini M, et al:Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome(TRAPS) with or without AA amyloidosis. Ann Rheum Dis 70:1511-1512, 2011.
PubMed
31) Gattorno M, Obici L, Cattalini M, et al:Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome(TRAPS):an open-label, phase II study. Ann Rheum Dis 76:173-178, 2017.
PubMed
32) Bodar EJ, Kuijk LM, Drenth JP, et al:On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 70:2155-2158, 2011.
PubMed
33) Arostegui JI, Anton J, Calvo I, et al:Open-label, phase II study to assess the efficacy and safety of Canaki-numab treatment in active hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheumatol 69:1679-1688, 2017.
 
34) Varan O, Kucuk H, Babaoglu H, et al:Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol 29:363-366, 2019.
PubMed
35) Ugurlu S, Ergezen B, Egeli BH, et al:Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary t o f amilial Mediterranean fever. Rheumatology(Oxford)keaa211, 2020.
 
P.218 掲載の参考文献
1) Presta LG, Lahr SJ, Shields RL, et al:Humanization of an antibody directed against IgE. J Immunol 151(5):2623-2632, 1993.
 
2) Boushey HA Jr:Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 108:77-83, 2001.
 
3) 日本アレルギー学会:喘息予防・管理ガイドライン 2018. 日本アレルギー学会喘息ガイドライン専門部会編. 協和企画, 東京. p95, 2018.
 
4) 荒井崇彦, 天野出月, 黨康夫ほか:当院においてオマリズマブを導入した重症喘息患者の臨床的検討. アレルギーの臨床 31(11):1086-1089, 2011.
 
5) Singh H, Peters JI, Kaur Y, et al:Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach:The Real-life Effective-ness of Omalizumab Therapy(REALITY)study. Ann Allergy Asthma Immunol 123(5):476-482, 2019.
 
6) Vennera MDC, Sabadell C, Picado C, et al:Duration of the efficacy of omalizumab after treatment discontinuation in'real life'severe asthma. Thorax 73(8):782-784, 2018.
PubMed
7) Domingo C, Pomares X, Navarro A, et al:A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients. Br J Clin Pharmacol 84(2):339-348, 2018.
 
8) Jackson K, Bahna S:Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Expert Rev Clin Immunol 16(3):311-319, 2020.
PubMed
9) Balbino B, Herviou P, Godon O, et al:The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors. J Clin Invest 130(3):1330-1335, 2020.
 
10) To Y, Kono Y, Tsuzuki R, et al:Rheumatoid arthritis-like polyarthralgia after the initiation of omalizumab treatment:a case series. J Aller Clin Immunol Pract (Accepted)
 
11) Labrosse R, Graham F, Roches AD, et al:The Use of Omalizumab in Food Oral Immunotherapy. Arch Immunol Ther Exp(Warsz)65(3):189-199, 2017.
 
12) Lieberman JA, Chehade M:Use of omalizumab in the treatment of food allergy and anaphylaxis. Curr Allergy Asthma Rep 13(1):78-84, 2013.
PubMed
P.227 掲載の参考文献
1) Okubo K, Kurono Y, Ichimura K, et al:Japanese guidelines for allergic rhinitis 2020. Allergol Int 69:331-345, 2020.
PubMed
2) Okubo K, Ogino S, Nagakura T, et al:Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 55:379-386, 2006.
PubMed
3) Okubo K, et al:Add-On Omalizumab for Inadequately Controlled Severe Pollinosis Despite Standard-of-Care:A Randomized Study. J Allergy Clin Immunol Pract 8:3130-3140, 2020.
PubMed
4) 中央社会保険医療協議会:最適使用推進GLが策定された医薬品の保険適用上の留意事項について(https://www.mhlw.go.jp/content/12404000/000565817.pdf)
 
5) 日本耳鼻咽喉科免疫アレルギー学会:鼻アレルギー診療ガイドライン-通年性鼻炎と花粉症-2020年版. 鼻アレルギー診療ガイドライン作成委員会編. ライフ・サイセンス, 東京. p71, 2020.
 
P.233 掲載の参考文献
1) 田中稔彦, 亀好良一, 秀 道広:広島大学皮膚科外来での蕁麻疹の病型別患者数. アレルギー 55:134-139, 2006.
Medical*Online
2) 秀 道広, 森 桶聡, 福永 淳ほか:蕁麻疹診療ガイドライン 2018. 日皮会誌 128:2503-2624, 2018.
 
3) Yamaguchi M, Lantz CS, Oettgen HC, et al:IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 185:663-672, 1997.
PubMed
4) Yamaguchi M, Sayama K, Yano K, et al:IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells:synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol 162:5455-5465, 1999.
PubMed
5) Kaplan AP, Gimene-Arnau AM, Saini SS:Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 72:519-533, 2017.
 
6) Kishimoto I, Kambe N, Ly NTM, et al:Basophil count is a sensitive marker for clinical progression in a chronic spontaneous urticaria patient treated with omalizumab. Allergol Int 68:388-390, 2019.
 
7) Maurer M, Gimenez-Arnau AM, Sussman G, et al:Ligelizumab for Chronic Spontaneous Urticaria. N Engl J Med 381:1321-1332, 2019.
PubMed
8) Maurer M, Rosen K, Hsieh HJ, et al:Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368:924-935, 2013.
 
9) Hide M, Igarashi A, Yagami A, et al:Efficacy and safety of omalizumab for the treatment of refractorychronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. Allergol Int 67:243-252, 2018.
 
10) Urgert MC, van den Elzen MT, Knulst AC, et al:Omalizumab in patients with chronic spontaneous urticaria:a systematic review and GRADE assessment. Br J Dermatol 173:404-415, 2015.
PubMed
11) Maurer M, Kaplan A, Rosen K, et al:The XTEND-CIU study:Long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol 141:1138-1139, 2018.
PubMed
12) Zuberbier T, Aberer W, Asero R, et al:The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73:1393-1414, 2018.
PubMed
P.240 掲載の参考文献
1) Papi A, Brightling C, Pedersen SE, et al:Asthma. Lancet 391(10122):783-800, 2018.
PubMed
2) Moore WC, Peters SP:Severe asthma:an overview. J Allergy Clin Immunol 117(3):487-494;quiz 495, 2006.
 
3) Hyland ME, Whalley B, Jones RC, et al:A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res 24(3):631-639, 2015.
PubMed
4) Yaghoubi M, Adibi A, Safari A, et al:The Projected Economic and Health Burden of Uncontrolled Asthma in the United States. Am J Respir Crit Care Med 200 (9):1102-1112, 2019.
PubMed
5) Wenzel S:Severe asthma:from characteristics to phenotypes to endotypes. Clin Exp Allergy 42(5):650-658, 2012.
PubMed
6) Woodruff PG, Modrek B, Choy DF, et al:T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180(5):388-395, 2009.
PubMed
7) Peters MC, Mekonnen ZK, Yuan S, et al:Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 133(2):388-394, 2014.
PubMed
8) Fitzpatrick AM, Moore WC:Severe Asthma Phenotypes -How Should They Guide Evaluation and Treatment? J Allergy Clin Immunol Pract 5(4):901-908, 2017.
PubMed
9) Lambrecht BN, Hammad H, Fahy JV:The Cytokines of Asthma. Immunity 50(4):975-991, 2019.
PubMed
10) Ortega HG, Liu MC, Pavord ID, et al:Mepolizumab treatment in patients with severe eosinophilic asthma. New Engl J Med 371(13):1198-1207, 2014.
PubMed
11) Pavord ID, Korn S, Howarth P, et al:Mepolizumab for severe eosinophilic asthma(DREAM):a multicentre, double-blind, placebo-controlled trial. Lancet 380 (9842):651-659, 2012.
 
12) Bel EH, Wenzel SE, Thompson PJ, et al:Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New Engl J Med 371(13):1189-1197, 2014.
PubMed
13) Castro M, Mathur S, Hargreave F, et al:Reslizumab for poorly controlled, eosinophilic asthma:a randomized, placebo-controlled study. Am J Respir Crit Care Med 184(10):1125-1132, 2011.
PubMed
14) Castro M, Zangrilli J, Wechsler ME, et al:Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3(5):355-366, 2015.
PubMed
15) Corren J, Lemanske RF, Hanania NA, et al:Lebriki-zumab treatment in adults with asthma. New Engl J Med 365(12):1088-1098, 2011.
 
16) Castro M, Wenzel SE, Bleecker ER, et al:Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma:a phase 2b randomised dose-ranging study. Lancet Respir Med 2(11):879-890, 2014.
PubMed
17) Bleecker ER, FitzGerald JM, Chanez P, et al:Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO):a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388(10056):2115-2127, 2016.
 
18) FitzGerald JM, Bleecker ER, Nair P, et al:Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma(CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388(10056):2128-2141, 2016.
PubMed
19) Haldar P, Brightling CE, Hargadon B, et al:Mepolizum-ab and exacerbations of refractory eosinophilic asthma. The New England journal of medicine 360(10):973-984, 2009.
 
20) Nair P, Pizzichini MM, Kjarsgaard M, et al:Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. New Engl J Med 360(10):985-993, 2009.
PubMed
21) Bel EH, Ortega HG, Pavord ID:Glucocorticoids and mepolizumab in eosinophilic asthma. New Engl J Med 371(25):2434, 2014.
PubMed
22) Powell C, Milan SJ, Dwan K, et al:Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev(7):CD010834, 2015.
PubMed
23) Magnan A, Bourdin A, Prazma CM, et al:Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy 71(9):1335-1344, 2016.
PubMed
24) Bjermer L, Lemiere C, Maspero J, et al:Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels:A Randomized Phase 3 Study. Chest 150(4):789-798, 2016.
 
25) Corren J, Weinstein S, Janka L, et al:Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma:Effects Across a Broad Range of Eosinophil Counts. Chest 150(4):799-810, 2016.
PubMed
26) Farne HA, Wilson A, Powell C, et al:Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 9:CD010834, 2017.
 
27) Nair P, Wenzel S, Rabe KF, et al:Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. New Engl J Med 376(25):2448-2458, 2017.
PubMed
28) Howarth P, Chupp G, Nelsen LM, et al:Severe eosinophilic asthma with nasal polyposis:A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol 145(6):1713-1715, 2020.
PubMed
29) Weinstein SF, Katial RK, Bardin P, et al:Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract 7(2):589-596.e583, 2019.
 
30) Chitguppi C, Patel P, Gandler A, et al:Effect of Benralizumab in Patients With Severe Eosinophilic Asthma and Chronic Rhinosinusitis With Nasal Polyps:A Case Series. Am J Rhinol Allergy doi: 10.1177/1945892420978351, 2020.
 
31) Shrimanker R, Keene O, Hynes G, et al:Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma:A Post Hoc Analysis. Am J Respir Crit Care Med 200(10):1308-1312, 2019.
PubMed
32) Khatri S, Moore W, Gibson PG, et al:Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 143(5):1742-1751. e1747, 2019.
 
33) Murphy K, Jacobs J, Bjermer L, et al:Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract 5(6):1572-1581 e1573, 2017.
 
34) Busse WW, Bleecker ER, FitzGerald JM, et al:Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 7(1):46-59, 2019.
PubMed
35) Chupp GL, Bradford ES, Albers FC, et al:Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma(MUSCA):a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5(5):390-400, 2017.
 
36) Nair P, Barker P, Goldman M:Glucocorticoid Sparing of Benralizumab in Asthma. The New Engl J Med 377 (12):1205, 2017.
PubMed
37) Dunn RM, Busse PJ, Wechsler ME:Asthma in the elderly and late-onset adult asthma. Allergy 73(2):284-294, 2018.
PubMed
38) Principe S, Benfante A, Calzetta L, et al:Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. World Allergy Organ J 12(11):100081, 2019.
PubMed
P.248 掲載の参考文献
1) Khoury P, Grayson PC, Klion AD:Eosinophils in vasculitis:Characteristics and roles in pathogenesis. Nat Rev Rheumatol 10:474-483, 2014.
PubMed
2) Lyons PA, Peters JE, Alberici F, et al:Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 10:5120, 2019.
PubMed
3) Berti A, Boukhlal S, Groh M, et al:Eosinophilic granulomatosis with polyangiitis:the multifaceted spectrum of clinical manifestations at different stages of the disease. Expert Rev Clin Immunol 16:51-61, 2020.
PubMed
4) 厚労省科学研究費補助金難治性疾患等政策研究事業. ANCA 関連血管炎 診療ガイドライン2017. 有村義宏, 丸山彰一, 本間栄編. 診断と治療社, 東京. 2017.
 
5) Furuta S, Iwamoto T, Nakajima H:Update on eosinophilic granulomatosis with polyangiitis. Allergol Int 68:430-436, 2019.
PubMed
6) Khoury P, Zagallo P, Talar-Williams C, et al:Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 67:1149-1156, 2012.
PubMed
7) Guillevin L, Pagnoux C, Seror R, et al:The five-factor score revisited:Assessment of prognoses of systemic necrotizing vasculitides based on the french vasculitis study group(FVSG)cohort. Medicine(Baltimore)90:19-27, 2011.
 
8) Groh M, Pagnoux C, Baldini C, et al:Eosinophilic granulomatosis with polyangiitis(Churg Strauss)(EGPA)Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26:545-553, 2015.
PubMed
9) Wechsler ME, Akuthota P, Jayne D, et al:Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376:1921-1932, 2017.
 
10) Nakazawa D, Masuda S, Tomaru U, et al:Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 15:91-101, 2019.
PubMed
11) Dougan M, Dranoff G, Dougan SK:GM-CSF, IL-3, and IL-5 Family of Cytokines:Regulators of Inflammation. Immunity 50:796-811, 2019.
 
12) Jakiela B, Szczeklik W, Plutecka H, et al:Increased production of IL-5 and dominant Th2 type response in airways of Churg-Strauss syndrome patients. Rheumatology(Oxford)51:1887-1893, 2012.
PubMed
13) Steinfeld J, Bradford ES, Brown J, et al:Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 143:2170-2177, 2019.
PubMed
14) Komai T, Harada H, Takahashi H, et al:Reduction of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody by Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis. J Clin Rheumatol 2020 Jun 18. doi:10.1097/RHU.0000000000001453 <Online ahead of print>.
 
15) Yates M, Watts RA, Bajema IM, et al:EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583-1594, 2016.
 
16) Kim S, Marigowda G, Oren E, et al:Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 125:1336-1343, 2010.
PubMed
17) Wong TW, Doyle AD, Lee JJ, et al:Eosinophils Regulate Peripheral B Cell Numbers in Both Mice and Humans. J Immunol 192:3548-3558, 2014.
PubMed
18) Takenaka K, Minami T, Yoshihashi Y, et al:Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis. Allergol Int 68:539-540, 2019.
PubMed
19) Khatri S, Moore W, Gibson PG, et al:Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 143:1742-1751, 2019.
 
20) Koike H, Akiyama K, Saito T, et al:Intravenous im-munoglobulin for chronic residual peripheral neurop-athy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome):a multicenter, double-blind trial. J Neurol 262:752-759, 2015.
 
21) Puechal X, Pagnoux C, Baron G, et al:Adding Aza-thioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis(Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis No-dosa Without Poor Prognosis Factors:A Randomized, Controlled Trial. Arthritis Rheumatol 69:2175-2186, 2017.
 
22) 厚生労働省科学研究費補助金難治性疾患等政策研究事業難治性血管炎に関する調査研究班:血管炎症候群の治療の手引き2020(パブリックコメント用データ).
 
P.256 掲載の参考文献
1) 加藤則人, 大矢幸弘, 池田政憲ほか:アトピー性皮膚炎診療ガイドライン2018. 日皮会誌 128:2431-2502, 2018.
 
2) SANOFI REGENERON:デュピクセント(R) 皮下注300mg シリンジ 添付文書. 2020年8月改訂(第2版)
 
3) Weidinger S, Beck LA, Bieber T, et al:Atopic dermatitis. Nat Rev Dis Primers 4:1, 2018.
PubMed
4) 厚生労働省:デュピルマブ(遺伝子組換え)製剤の最適使用推進ガイドライン2018(アトピー性皮膚炎)(https://www.dermatol.or.jp/uploads/uploads/files/news/G20180419_guideline.pdf).
 
5) Rabe KF, Nair P, Brusselle G, et al:Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med 378:2475-2485, 2018.
PubMed
6) Blauvelt A, Bruin-Weller M, Gooderham M, et al:Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids(LIBERTY AD CHRONOS):a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287-2303, 2017.
 
7) Simpson E, Bieber T, Guttman-Y E, et al:Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 375:2335-2348, 2016.
 
8) 鳥居薬品株式会社:コレクチム(https://www.corectim.jp/)
 
9) Yang H, Wang J, Zhang X, et al:Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis A Systematic Review and Meta-analysis. JAMA Dermatol 155:585-593, 2019.
 
10) Kabashima K, Matsumura T, Komazaki H, et al:Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. N Engl J Med 383:141-150, 2020.
PubMed
11) サノフィ(株):デュピクセント(R) 投与前チェックリスト(アトピー性皮膚炎)(https://www.dupixent.jp/product)
 
12) サノフィ(株):EASI アトラス
 
P.261 掲載の参考文献
1) Howard M, Farrar J, Hilfiker M, et al:Identification of a T cell-derived b cell growth factor distinct from interleukin 2. J Exp Med 155:914-923, 1982.
 
2) Brown KD, Zurawski SM, Mosmann TR, et al:A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142:679-687, 1989.
PubMed
3) Wills-Karp M, Luyimbazi J, Xu X, et al:Interleukin-13:central mediator of allergic asthma. Science 282:2258-2261, 1998.
PubMed
4) Risse PA, Jo T, Suarez F, et al:Interleukin-13 inhibits proliferation and enhances contractility of human airway smooth muscle cells without change in contractile phenotype. Am J Physiol Lung Cell Mol Physiol 300: L958-L966, 2011.
PubMed
5) Wang T, Secombes CJ:The evolution of IL-4 and IL-13 and their receptor subunits. Cytokine 75:8-13, 2015.
PubMed
6) Rothenberg ME:Eosinophilia. N Engl J Med 338:1592-1600, 1998.
PubMed
7) Bousquet J, Chanez P, Lacoste JY, et al:Eosinophilic inflammation in asthma. N Eng J Med 323:1033-1039, 1990.
 
8) Green RH, Brightling CE, McKenna S, et al:Asthma exacerbations and sputum eosinophil counts:a randomised controlled trial. Lancet 360:1715-1721, 2002.
 
9) Kouro T, Takatsu K:IL-5 and eosinophilic mediated inflammation:from discovery to therapy. Int Immunol 21:1303-1309, 2009.
PubMed
10) Nakagome K, Nagata M:Involvement and Possible Role of Eosinophils in Asthma Exacerbation. Front Immunol 9:2220, 2018.
PubMed
11) Fukuda T, Fukushima Y, Numao T, et al:Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Am J Respir Cell Mol Biol 14:84-94, 1996.
PubMed
12) Yamamoto H, Nagata M, Sakamoto Y:CC chemokines and transmigration of eosinophils in the presence of vascular cell adhesion molecule 1. Ann Allergy Asthma Immunol 94:292-300, 2005.
PubMed
13) Noguchi T, Nakagome K, Kobayashi T, et al:Periostin upregulates the effector functions of eosinophils. J Allergy Clin Immunol 138:1449-1452, 2016.
PubMed
14) van Rijt LS, Jung S, Kleinjan A, et al:In vivo depletion of lung CD11c+dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med 201:981-991, 2005.
PubMed
15) To Y, Dohi M, Tanaka R, et al:Early interleukin 4-dependent response can induce airway hyperreactivity before development of airway inflammation in a mouse model of asthma. Lab Invest 81:1385-1396, 2001.
 
16) Nakagome K, Dohi M, Okunishi K, et al:Antigen-sensitized CD4+CD62Llow memory/effector T helper 2 cells can induce airway hyperresponsiveness in an antigen free setting. Respir Res 6:46, 2005.
 
17) Matsunaga K, Hirano T, Akamatsu K, et al:Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. Allergol Int 60:331-337, 2011.
PubMed
18) Kanemitsu Y, Matsumoto H, Izuhara K, et al:Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 132:305-312, 2013.
PubMed
19) Wenzel S:Severe asthma:from characteristics to phenotypes to endotypes. Clin Exp Allergy 42:650-658, 2012.
PubMed
20) Ortega HG, Liu MC, Chanez P, et al:Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198-1207, 2014.
PubMed
21) Corren J, Lemanske RF, Hanania NA, et al:Lebriki-zumab treatment in adults with asthma. N Engl J Med 365:1088-1098, 2011.
 
22) Hanania NA, Korenblat P, Chapman KR, et al: Efficacy and safety of lebrikizumab in patients with uncontrolled asthma(LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4:781-796, 2016.
PubMed
23) Castro M, Corren J, Pavord ID, et al:Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 378:2486-2496, 2018.
PubMed
24) Rabe KF, Nair P, Brusselle G, et al:Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med 378:2475-2485, 2018.
PubMed
25) Simpson EL, Bieber T, Guttman-Yassky E, et al:Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 375:2335-2348, 2016.
PubMed
26) Bachert C, Han JK, Desrosiers M, et al:Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps(LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52):results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394:1638-1650, 2019.
PubMed
27) Maspero JF, Katelaris CH, Busse WW, et al:Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. J Allergy Clin Immunol Pract 8:527-539, 2020.
 
P.270 掲載の参考文献
1) Sepriano A, Kerschbaumer A, Smolen JS, et al:Safety of synthetic and biological DMARDs:A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 79:S760-S770, 2020.
 
2) レミケード点滴静注用, 使用成績調査(全例調査)報告書 Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis Ann Rheum Dis 67:189-194, 2008.
 
3) エンブレル皮下注用, 適正使用情報(全例調査結果)Vol.9. 2010年7月.
 
4) アクテムラ点滴静注用, 全例調査 最終報告
 
5) オレンシア点滴静注用, 適正使用情報 Vol.4 最終報告概要
 
6) ヒュミラ皮下注, 適正使用情報 Vol.7 最終報告概要
 
7) 日本呼吸器学会:生物学的製剤と呼吸器疾患・診療の手引き.生物学製剤と呼吸器疾患・診療の手引き作成委員会編. 2014年
 
8) Holroyd CR, Seth R, Bukhari M, et al:The British society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary. Rheumatol(United Kingdom)58:220-226, 2019.
 
9) 日本リウマチ学会:関節リウマチ(RA)に対するTNF阻害薬使用の手引き(2020年2月1日改訂版)
 
10) 日本リウマチ学会:関節リウマチ(RA)に対するIL-6阻害薬使用の手引き(2020年2月1日改訂版)
 
11) 日本リウマチ学会:関節リウマチ(RA)に対するアバタセプト使用の手引き(2020年2月1日改訂版)
 
12) 日本リウマチ学会:免疫抑制・化学療法により発症する B型肝炎対策ガイドライン(改訂版). 2011年9月26日
 
13) 日本肝臓学会:B型肝炎治療ガイドライン(第3.2版).肝炎治療ガイドライン作成委員会編.2020年7月
 
14) Simon TA, Thompson A, Gandhi KK, et al:Incidence of malignancy in adult patients with rheumatoid arthritis:a meta-analysis. Arthritis Res Ther 17:212, 2015.
PubMed
15) Koike R, Takeuchi T, Eguchi K, et al:Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17:451-458, 2007.
PubMed
16) Saag KG, Teng GG, Patkar NM, et al:American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762-784, 2008.
PubMed
17) Pham T, Claudepierre P, Deprez X, et al:Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Societe Francaise de Rhumatologie, SFR). Joint Bone Spine 72(suppl 1):S1-S58, 2005.
 
18) Ochi S, Saito K, Mizoguchi F, et al:Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. Arthritis Res Ther 22:41, 2020.
PubMed
19) Kawabe A, Nakano K, Kubo S, et al:Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. Arthritis Res Ther 22:136, 2020.
PubMed
20) Nakano K, Saito K, Nawata A, et al:Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. Mod Rheumatol 31:94-100, 2021.
PubMed

書評

最近チェックした商品履歴

Loading...